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ABSTRACT
ASPECTS OF MITOCHONDRIAL OXIDATIVE METABOLISM
by

Leslie Kushner
Adviser: Dr. Horst Schulz

The effects of metabolic intermediates and coenzymes on the activities of
fa tty acyl-CoA synthetase and carnitine palm itoyltransferase (CPT) in rat
heart m itochondria were studied.

ADP and palm itoyl-/-carnitine were weak

inhibitors of fa tty acyl-CoA synthetase.
/u.M succinyl-CoA.

CPT A was inhibited 59.3% by 100

However, succinate thiokinase activity in ra t heart cytosol

was too low to m aintain a succinyl-CoA concentration sufficient to affect the
activity of CPT A.

There was no indication th a t fa tty acid oxidation in rat

heart m itochondria is controlled via the regulation of either CPT A or fatty
acyl-CoA synthetase.

The dependence of the oxidation of unsaturated fa tty acids containing cis
double bonds on the presence of 3-hydroxyacyl-CoA epimerase was investi
gated.

The specific activity of epimerase in ra t heart mitochondria was found

to be significantly low er than the rate of linoleoyl-CoA oxidation.

Thus, it is

the NADPH-dependent 2,4-dienoyl-CoA reductase, not the 3-hydroxyacyl-CoA
epimerase, which functions in the oxidation of polyunsaturated fa tty acids.
[C.-H. Chu, L. Kushner, D. Cuebas, and H. Schulz, Biochem. Biophys. Res.
Comm., vol. 118, pp. 162-167, 1984]

- iv -

3-M ercaptopropanoyl-CoA and S-acetyl-3-mercaptopropanoyl-CoA, phy
siological metabolites of the known convulsant 3-mercaptopropanoic acid, were
examined fo r their effects on purified pyruvate dehydrogenase complex from
porcine and bovine heart.

Both 3-mercaptopropanoyl-CoA and S-acetyl-3-

mercaptopropanoyl-CoA were found to be inhibitors of th is enzyme.
optim al

conditions,

50%

inhibition

was

obtained

at

12.6

Under
/tM

3-

mercaptopropanoyl-CoA or 5.2 fxM S-acetyl-3-mercaptopropanoyl-CoA w hile
100 fxM of the la tte r compound gave 90% inhibition.

The inhibition observed

w ith S-acetyl-3-mercaptopropanoyl-CoA was dem onstrated to be irreversible.
M aximal inhibition of the complex and its component enzymes was observed
when it w as reacted w ith the inhibitor under conditions which promote reduc
tion of the endogenous lipoate.

[L. Kushner, D. Cuebas, and H. Schulz, Fed.

Proc., vol. 43(7), pp. 1870, 1984]

Prelim inary

results

indicate

th a t

S-acetyl-3-mercaptopropanoyl-CoA

formed intram itochondrially inhibits pyruvate-supported respiration in ra t
heart and liver mitochondria.
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INTRODUCTION
Oxidation of fats and carbohydrates is a major mechanism by w hich cells
obtain energy.

In glycolysis, glucose is broken dow n to pyruvate in a series of

reactions which occur in the cytosol.

The pyruvate formed enters th e m ito

chondria to be converted to acetyl-CoA by the pyruvate dehydrogenase com
plex.

F atty acids are degraded to acetyl-CoA in mitochondria via the /3-

oxidation pathw ay.

The acetyl-CoA th u s formed may either enter the TCA

cycle to provide additional cellular energy or the citrate derived from the
acetyl-CoA may leave the mitochondria and eventually supply acetate units
which serve as building blocks for fa tty acid synthesis.

The relative activities

of each of these pathw ays depends on the tissue being studied and the physio
logical state of the organism.

These tw o factors play a role in regulation of

key enzymes of fa tty acid and carbohydrate oxidation.

In mammalian liver, there is a reciprocal relationship between fa tty acid
and carbohydrate metabolism .1 In the carbohydrate-fed state, carbohydrates
are oxidized and fa tty acid synthesis occurs, w hile fa tty acid oxidation is
suppressed.

In the carbohydrate-starved state, fa tty

acid synthesis is

suppressed, while gluconeogenesis and fa tty acid oxidation are the prim ary
metabolic activities.2 A major point in regulation of these metabolic pathw ays
is thought to be the carnitine acyltransferase (CPT)(EC 2.3.1.21) system which
is located in the inner mitochondrial m em brane.1

In mammalian heart, fa tty acids are the main substrate fo r energy m eta
bolism,3 although glycolysis does occur. De novo fa tty acid synthesis is not
thought to be a major metabolic pathw ay in heart.

However, some fa tty acid

elongation and complex lipid synthesis does occur in this tissue.

Regulation of

-2-

these processes in heart tissue is not completely understood.

In tissues which oxidize fa tty acids, the long-chain fa tty acids in the cyto
sol m ust be activated by the enzyme fa tty acy 1-coenzyme A synthetase (EC
6.2.1.3), which is located in the outer m itochondrial membrane4,5 , the endo
plasmic reticulum 6, 7 , and probably the peroxisome.

The activated fa tty acyl

moiety can either be channeled into lipid biosynthesis or /3-oxidation.8 In order
for 3-oxidation to occur, the fa tty acyl moiety m u st cross the inner mitochon
drial membrane.

For long-chain fa tty acyl groups, this process is facilitated

by the carnitine acyltransferase system.

It has been suggested th a t fa tty acid

activation and/or the carnitine acyltransferase reactions function as points of
regulation in mammalian heart tissue.

U nsaturated fa tty acids are also degraded by 3-oxidation in both liver and
heart tissue.

However, there is controversy over the enzymatic requirements

for the shifting or removal of the double bonds and over the subcellular loca
tion of the enzymes involved.

The subcellular location of the enzymes is

im portant since com partm entalization w ould have a bearing on the regulation
of this metabolic process.

All tissues have the capacity fo r glycolysis.

The final product of this

pathw ay, pyruvate, is either reduced to lactate or oxidized in mitochondria.
The pyruvate dehydrogenase complex is a key regulatory enzyme of the oxida
tive metabolism of pyruvate in the mitochondria.

There is a reciprocal rela

tionship between the oxidation of carbohydrates and fa tty acids.9 This recipro
city is dependent on the synthetic needs of the cell, the energy dem and of the
cell, the availability of the different substrates, and the accumulation of

- 3-

products.

An increase in the intram itochondrial NADH/NAD+ ratio w ill inhi

bit the TCA cycle10 , the 3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35)
reaction10 of /3-oxidation, and the pyruvate dehydrogenase complex.11’ 12, 13 An
increase in the acetyl-CoA/CoASH ratio w ill inhibit both the 3-ketoacyl-CoA
thiolase (EC 2.3.1.16) reaction14 of /3-oxidation and the pyruvate dehydro
genase reaction.11’ 12’13 Factors which affect the key enzyme, pyruvate dehy
drogenase complex, have an im portant bearing on the carbohydrate metabolism
of all tissues.

However, this is most critical in the brain, which has little, if

any, capacity for /3-oxidation and derives m ost of its metabolic energy from
glucose oxidation.15’ 16> 17

R egulation

o f F a tty Acyl-CoA S y n th e ta se an d C a rn itin e P a lm ito y l

tra n s fe ra s e o f M am m alian H eart M ito c h o n d ria

F atty acids are the main substrates fo r energy metabolism in heart m us
cle.3 Although the metabolic steps of /3-oxidation are well established, the regu
lation of this pathw ay in heart muscle is not y et fu lly understood.

Long-chain fa tty acids in the cytosol m ust be activated by the enzyme
fa tty acyl-coenzyme A synthetase (EC 6.2.1.3), which is located in the outer
mitochondrial membrane.4’5 This process may facilitate the translocation of
activated fa tty acids across the outer membrane.18 In heart tissue, the activated
fa tty acyl moiety can either be channeled into lipid biosynthesis or /3oxidation.8 In order for /3-oxidation to occur, the fa tty acyl moiety m ust cross
the inner mitochondrial membrane.

For long-chain fa tty acyl groups, this pro

cess is facilitated by the carnitine acyItransferase (CPT) (EC 2.3.1.21) sys
tem .J9’ 20’21

-4 -

There

are

tw o

CPT

enzymes

in

the

inner

m itochondrial

mem

brane20, 22,23,24,25,26,27,28>29 : CPT A25,2^’ 27 or I28' 29 is loosely attached to
the outer surface of the inner mitochondrial membrane; CPT B25,26,27 or
II28,29 is located on the inner surface of the inner mitochondrial membrane (see
Figure 1).

Hoppel19 presents a convincing argument th a t the CPT I and II of

Kopec and Fritz28, 29 are both CPT B.

Kopec and Fritz29 prepared antibodies to purified CPT I.
IG-I, inhibited the activity of only purified CPT I.

One preparation,

A nother preparation, IG-II,

inhibited the activity of both purified CPT I and p artially purified CPT II.
Brosnan et al. 20 showed th a t IG-II of Kopec and Fritz29 inhibited the CPT
reaction on both the externai and internal surface of the inner mitochondrial
membranes by 60% and 88%, respectively, w hile IG-I inhibited the CPT reac
tion only on the external surface of the inner mitochondrial membrane, also by
60%.

They concluded th a t the tw o CPT reactions are not catalyzed by identi

cal enzymes.

If, as Hoppel19 believes, the CPT I and II of Kopec and Fritz28,29

are both CPT B, then tw o fu rth er conclusions are possible: although both CPT
enzymes are identical (or have some identical regions), the CPT A is more
exposed to the external milieu than CPT B, th u s exposing an additional
antigenic determ inant; or th a t the CPT B transverses the membrane and is
exposed on both sides of the membrane.

This last possibility is unlikely since

trypsinization of the digitonin "m itoplast" left the CPT B activity intact.30

Although CPT A and CPT B have the same catalytic activity (both
enzymes catalyze the forw ard and reverse reactions31 ), kinetic differences
between the tw o enzymes have been dem onstrated.27 The CPT from beef heart
mitochondria was purified as a single protein.32,33,34 In addition, Bremer et

-5 -

al.,35 present evidence th a t there are no distinct inner and outer CPT enzymes.
W hen the inner and outer CPT were purified from ra t liver mitochondria
separately, they were show n to be kinetically and immunologically identical
and have identical m olecular weights.30 However, these same researchers
dem onstrated th a t there are differences between the inner and outer CPT in the
intact mitochondrial membrane.30 It is likely th a t CPT A and CPT B are identi
cal enzymes, altered in some w ay by th eir different locations in the mitochon
drial membrane.

It has been suggested th a t fa tty acid activation36, 37 or the carnitine acyltransferase reactions may function as points of regulation for /3-oxidation in
mammalian heart tissue.

In the perfused rat heart, at low levels of ventricular pressure, an increase
in the concentration of palm itate in the perfusate causes a proportional increase
in the rate of palm itate uptake.

This is associated w ith a slight increase in tis

sue levels of long-chain acyl-CoA, acyl-cam itine, acetyl-CoA, and acetylcarnitine. When the concentration of palm itate is increased above 0.6 mM, the rate
of uptake does not increase further.

In addition, the rate of oxygen consump

tion and 14C 0 2 production from labelled palm itate remains constant.

How

ever, large am ounts of acyl-CoA and acyl-cam itine derivatives accumulate in
the tissue.

W hile the mass action ratio for CPT remains constant as the palmi

tate concentration is increased, the mass action ratio of carnitine acetyl
transferase shifts tow ard acetyl-CoA form ation.

Under these conditions, it

appears th a t at palm itate concentrations in the perfusate between 0 and 0.6
mM, /3-oxidation is lim ited by the rate of palm itate uptake or activation.

At

higher levels of palm itate, the rate of fa tty acid uptake is lim ited by the

-6 -

availability of free CoASH an d /o r carnitine which are required fo r th e fa tty
acyl-CoA synthetase and the carnitine acyl transferase reactions, respectively.
This finding is supported by the fact th a t acetyl-CoA oxidation through the
TCA cycle is not accelerated under conditions of high exogenous palm itate con
centration and also by the fact th a t the tissue ratios of acetyl-CoA/CoASH and
acetylcam itine/cam itine continue to increase.38

A vailability of carnitine m ay be a factor in lim iting the rate of CPT A,
w hile availability of CoASH may be a factor in lim iting the rate of either the
fa tty acyl-CoA synthetase or CPT B.

However, the effect of substrate availa

bility on these enzymes may not be the lim iting factor for /3-oxidation since the
products of both reactions accumulate in the tissue.

The subcellular locations

of the metabolites measured and their concentration changes in each subcellular
com partm ent (cytosol and m itochondria) under the conditions studied are more
significant than whole tissue levels in determining the participation of CPT in
lim iting /3-oxidation and in determining w hether the CPT enzymes could be
controlled by changes in substrate availability.

Cytosolic and mitochondrial levels of CoASH and carnitine in rat heart
and liver tissue have been estim ated.37 Nearly all of the heart tissue CoASH
was m itochondrially located, and 92% of this was free CoASH.
30% of the free CoASH was located in the cytosol.

In the liver,

In both tissues it was

determ ined th a t 100% of the free carnitine was in the cytosol.

This is prob

ably an overestimation due to the loss of free carnitine during the preparation
of mitochondria.

The carnitine acylcam itine translocase facilitates the equili

bration of free carnitine across the mitochondrial inner membrane.39 W hile this
w ould function to m aintain the same carnitine concentration in the cytosolic

- 7-

and mitochondrial com partm ents of the cell, it w ould also allow carnitine loss
f rom mitochondria during the preparation of this organelle.

The maximal concentration of free CoASH in the cytosol w as determined
to be 22 /iM , but it w ould probably alw ays be less due to the presence of some
acyl-CoA.37 The Km fo r CoASH fo r the fa tty acyl-CoA synthetase is 7 //.M but
is 24

/j . M

in the presence of 8 /zM palm itoyl-CoA .37

These data do suggest, however, th a t the availability of free CoASH in the
cytosol of heart tissue could be a limiting factor fo r fa tty acid activation, and
thus, /3-oxidation.

There is evidence that the availability of free CoASH in the

cytosol of brown adipose tissue is a lim iting factor for fa tty acid activation in
th a t tissue.40

When acetyl-CoA oxidation in heart tissue is increased by increasing ven
tricular pressure, the rate of palm itate uptake and /3-oxidation is also
increased.38 This is associated w ith a decrease in tissue levels of fa tty acids,
acyl-CoA, acetyl-CoA, and acetyl-cam itine, and w ith an increase in tissue lev
els of acyl-cam itine, free CoASH, and free carnitine.38 When palm itate is
replaced by octanoate, which is able to cross the inner mitochondrial membrane
bypassing both activation and the transfer to carnitine41 , oxidation is fast
enough to m aintain high tissue levels of acetyl-CoA.

This occurs even when

fa tty acid oxidation is accelerated by increased ventricular pressure.38 It can be
inferred th at the rate of /3-oxidation may be limited by the availability of sub
strate inside the mitochondria, which is dependent on the activation and
transferase rates.

Palmitoyl-CoA is an inhibitor of fa tty acyl-CoA synthetase, w ith a Ki of
5 /zM.

The inhibition can be relieved by addition of CoASH or album in.37

Since, in vivo, m ost of the cytosolic palmitoy 1-CoA is probably bound by pro
tein, and since the carnitine level in the cytosol is quite high37 , thereby tending
to drive any palm itoyl-CoA formed to palm itoy 1-carnitine, the inhibition of
fa tty acid activation by palm itoy 1-CoA is probably not physiologically
significant.

An exception w ould be in the ischemic heart, where the cytosolic

concentration of acyl-CoA is estim ated to rise as high as 17 /zM.37

The other products of the fa tty acyl-CoA synthetase reaction, AMP and
pyrophosphate, were found to be inhibitory at 1 mM.

Acetyl-CoA, acetylcar-

nitine, NAD+, NADH, glucose-6-phosphate, pyruvate, and TCA cycle inter
mediates do not inhibit the reaction at 1 mM.37

Rat liver microsomal palm itate activation is inhibited by 5 mM AMP,
ADP, and cyclic-AMP by 48%, 40%, and 40%, respectively.42 Rat liver mito
chondrial palm itate activation is also inhibited by AMP and pyrophosphate.43

Total activity of the fa tty acy 1-CoA synthetase in various tissues, includ
ing heart mitochondria, has been shown to be greater than th at required to sup
port the highest rates of /3-oxidation and lipid biosynthesis.10-44 However,
N ormann et al.,36 found the fa tty acyl-CoA synthetase of intact ra t heart
mitochondria to have a four-fold lower activity than th e CPT A.

Regulation

of fa tty acid activation in vivo, may make this the rate-controlling step of /3oxidation.

The stim ulation of palm itate oxidation in ra t skeletal muscle mito

chondria caused by salicylic acid was due to the effect of this compound on the
fa tty acy 1-CoA synthetase.45 The fact th a t modification of the fa tty acid
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activation step affects the entire /3-oxidation pathw ay implicates this as the rate
limiting step.

W hile it is likely th a t availability of cytosolic CoASH is a

means of physiological regulation of this enzyme37 (for opposing view, see
Pande, 197144 , 197246 ), other means of regulation have not been fu lly inves
tigated.

Examination of fa tty acy 1-CoA synthetase has been done prim arily on tis
sue other than heart, because it was thought th a t heart mitochondria did not
possess this enzyme.

Recently, it was dem onstrated th a t lack of enzyme

activity was due only to the method of preparation of ra t heart mitochon
dria.4, 42 The protease, nagase was included in the preparation.

This enzyme

selectively inactivates fa tty acyl-CoA synthetase w ithout an effect on the other
enzymes of /3-oxidation.4

Possible inhibitors of fa tty acy 1-CoA synthetase include ketone bodies,
glycolytic intermediates, and ADP.

These compounds were tested for their

effect on fa tty acyl-CoA synthetase in rat heart mitochondria isolated w ithout
nagase.

Palm itoy 1-camitine is also a likely inhibitor of fa tty acyl-CoA synthetase.
In addition to its structural sim ilarity to palm itate, the concentration of long
chain acyl-cam itines has been dem onstrated to increase in heart tissue during
reduced oxidative m etabolism .38 In order to stu d y the effect of palm itoy 1cam itine on fa tty acyl-CoA synthetase, an attem pt was made to partially
purify the enzyme, i.e. to separate fa tty acy 1-CoA synthetase activity from car
nitine palm itoyltransferase activity.

This was undertaken because in ra t heart

mitochondria the specific activity of both enzymes is the same.

Since
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palm itoyl-CoA has been show n to inhibit the synthetase,37 CPT operating in
the reverse direction may cause an apparent inhibition due to accumulation of
the CoA derivative - an inhibition which w ould be indistinguishable from th at
due to the added carnitine derivative.

It has been suggested th a t some factor in the cytosol stim ulates the
activity of the fa tty acyl-CoA synthetase.47*48 Aas and Dale2 have shown th at
refeeding of carbohydrate-starved rats causes a decrease in the fa tty acid
activation rate in liver and heart.

Since the changes observed in liver are asso

ciated w ith hormonal changes, the possibility exists th a t the effector of fa tty
acyl-CoA synthetase is a kinase or phosphatase.

Streptozotocin-induced dia

betes caused a reduced rate of |3-oxidation and fa tty acy 1-CoA synthetase
activity in rat brown adipose tissue.49 In addition, adm inistration of Otetradecanoylphorbol 13-acetate (TPA) decreased fa tty acyl-CoA synthetase
activity in ra t adipocytes.50 This compound is known to exert its effects on
protein kinase C.51,52 Noradrenaline also caused a decrease in fa tty acyl-CoA
synthetase activity in adipose tissue.50 Cyclic AMP, an activator of certain pro
tein kinases, stim ulated /3-oxidation in ra t hepatocytes.53 The possibility of
activation

or inactivation

of rat

heart

fa tty

acyl-CoA

synthetase

by

phosphorylation-dephosphorylation was investigated.

In mammalian liver, there is a relationship between fa tty acid and car
bohydrate m etabolism .1 In the carbohydrate-fed state, carbohydrates are u til
ized and fa tty acid synthesis occurs, w hile fa tty acid oxidation is suppressed.
In this state the tissue level of m alony 1-CoA is high.

In the carbohydrate-

starved state, fa tty acid synthesis and malonyl-CoA production is suppressed,
w hile fa tty acid oxidation, gluconeogenesis, and ketogenesis are the prim ary
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metabolic activities.

Under these conditions, CPT activity in liver is

increased.2 In fact, it has been shown th a t the outer CPT activity increases to a
much greater extent than total CPT activity.54 Simultaneously, hepatic carni
tine levels and fa tty acy 1-CoA levels increase.

It has been dem onstrated th a t

high levels of carnitine55 and fa tty acyl-CoA1 stim ulate /3-oxidation, while
high levels of m alony 1-CoA inhibit /3-oxidation.56 The site of malony 1-CoA
inhibition has been identified as the CPT A.56,57,58>59 Recent evidence indicates
th a t total CPT may be sensitive to malony 1-CoA inhibition.35' 60 In addition,
sensitivity of CPT a ,54’61’62’63’64 ketogenesis65 and palm itate oxidation66’67
to malonyl-CoA changes w ith the physiological state of the organism.
W hether this is due to a change in the CPT A protein or a movement of CPT B
to exposure on the outer surface54 is not known.

O ther evidence indicates that

the changes in sensitivity of CPT to malony 1-CoA inhibition do not depend on
a change in the CPT enzyme itself, bu t on some other " regulatory" component
of the membrane35’ 60> 68 and may actually involve the synthesis of some new
protein.69 The existence of a membrane regulatory component is supported by
recent data which indicate th a t the malonyl-CoA binding site for ra t liver,
heart, and skeletal muscle mitochondria is distinct from the active site of CPT
A.70 In any case, such changes in kinetics indicate th at this is a regulated
enzyme.

C arbohydrate-starvation54’62> 64> 71> 72 and

streptozotocin-induction

of

ketosis and diabetes61, 73 in rats have the same effect of diminishing the sensi
tiv ity of liver mitochondria CPT A to malony 1-CoA. Treatm ent of diabetic
anim als w ith insulin not only reverses ketosis, b u t increases the sensitivity of
CPT A to malony 1-CoA.73 This indicates th a t this enzyme or regulation of this
enzyme is under hormonal control.
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The evidence th a t CPT is a point of regulation fo r /3-oxidation in mam
malian heart tissue is not as convincing.

Studies done to estimate cytosolic carnitine concentration37 reveal th a t this
substrate is probably not limiting to the CPT A reaction in heart tissue.

Fong and Schulz74 dem onstrated th a t the activities of CPT, 3-ketoacylCoA thiolase, and 3-hydroxyacyl-CoA dehydrogenase are nearly equal and
low er than other enzymes of /3-oxidation in ra t heart m itochondria.

They con

cluded th a t inhibition of any of these enzymes could result in inhibition of 8oxidation.

On the other hand, Pande44 showed th a t m itochondria from red and w hite
skeletal muscle of rabbit and heart and liver of ra t respired as rapidly w ith
palm itoy 1-CoA and carnitine as substrates as w ith palm itoy 1-carnitine
indicates th a t CPT A does not lim it /8-oxidation under norm al conditions.

This
In

addition, CPT activity in rat heart and liver mitochondria and in skeletal mus
cle mitochondria expressed in nmoles palm itoy 1-carnitine form ed/m in/m g pro
tein was alw ays greater than /3-oxidation expressed in nmoles palm itoy 1 group
consum ed/m in/m g protein.

However, the method used to assay for CPT

activity did not distinguish between CPT A and CPT B, nor was th e buffer used
isoosmotic w ith the mitochondrial m atrix.

Therefore, values obtained for CPT

activity probably reflect the sum of CPT A and CPT B activity.

It is still possible th a t accumulation of some m etabolite in the cytosol has
an inhibitory effect on CPT A, and thereby affects the rate of 3-oxidation by
limiting the am ount of substrate reaching the mitochondrial com partm ent.
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This seems to be the case for liver, where it has been shown th a t the rate
of fa tty acid synthesis can be horm onally modulated.

Control of th is process

using glucagon showed a positive correlation between the rate of fa tty acid syn
thesis and tissue malonyl-CoA concentration.75, 76 Both of these parameters
correlated inversely w ith long-chain acyl-cam itine concentration and the fa tty
acid oxidation rate.76 In addition, it was shown th a t about 60% of the to tal
CPT was sensitive to malonyl-CoA inhibition, w hile the remainder w as to tally
resistant.

The response of the sensitive CPT to increasing m alonyl-CoA con

centration was paralleled by the effect on palm itate and palm itoy 1-CoA oxida
tion, but showed no effect on the oxidation of palm itoy 1-carnitine.57

The CPT of heart mitochondria,77 brown adipose tissue mitochondria, 78
muscle mitochondria,79 and
malony 1-CoA.

brain

mitochondria,80 is also inhibited

by

In fact, CPT A from heart, muscle and adipose tissue was

shown to be about 50 times more sensitive to malonyl-CoA than is the CPT A
from liver.

By adjusting the assay m ixture w ith KC1 and sucrose to be

isoosmotic w ith the mitochondrial m atrix, Saggerson77 dem onstrated that, in
intact heart mitochondria, 93% of the overt CPT activity could be inhibited by
malony 1-CoA.

Thus, it is the CPT A th a t is malonyl-CoA sensitive.

Since fa tty acid synthesis is a major metabolic pathw ay in liver and it has
already been demonstrated th a t tissue levels of malonyl-CoA fluctuate, it is
likely th a t malony 1-CoA accumulates in the cytosol of this tissue and inhibits
CPT A. However, heart tissue does not actively synthesize fa tty acids.

Thus,

it would be unlikely th a t malonyl-CoA appears in the cytosol of heart tissue in
significant concentration.

This has been disputed by McGarry et al.,81 who

estimated total tissue contents of malonyl-CoA to be 2-8 nm ol/g w et w t in
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liver, heart and skeletal muscle of fed rats.

In addition, th e complex kinetic

changes observed concerning CPT sensitivity to m alonyl-CoA in ra t liver m ito
chondria are not seen in intact ra t heart mitochondria,35 nor are they seen in
brain mitochondria.82

Aas and Dale2 observed changes in CPT activity in liver during fasting and
refeeding, but not in heart.

Therefore, it is unlikely th a t the CPT A of ra t

heart mitochondria is regulated by the same mechanism as th a t of ra t liver
mitochondria.

Possible inhibitors of CPT A include ketone bodies, glycolytic interm edi
ates, ADP, ATP, NAD+, NADH. and carnitine derivatives.

These compounds

were tested for their effects on the CPT activity in ra t heart mitochondria.

In

additon, CoASH derivatives w ith stru ctu ral sim ilarities to malonyl-CoA have
been tested for their effects on CPT A activity in intact ra t heart mitochondria.
The mitochondria were kept intact by adjusting the osm olarity of the assay
m ixture w ith KC1 and sucrose to be isoosmotic w ith the m itochondrial m atrix.
The intactness of the m itochondria is significant when examining the effect of
CoASH derivatives on CPT A for several reasons: at the low level of inhibitor
used, a significant am ount can be lost due to the thioesterase activity present in
the mitochondrial m atrix 83 , th u s masking the inhibition; and it has been
dem onstrated th a t

m alonyl-CoA

only inhibits

the

membrane-associated

enzyme and not the solubilized enzyme,57,59 although this has been disputed.35
If other CoASH derivatives act sim ilarly to malonyl-CoA, then the intactness
of the mitochondrial membrane m ust be ensured in order to observe the inhibi
tion.
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Oxidation of Unsaturated Fatty Acids in Mammalian Heart and Liver
Mitochondria
Although the metabolic steps of /3-oxidation of saturated fa tty acids is
w ell known, the oxidation pathw ay of unsaturated fa tty acids containing cis
double bonds has not been fu lly elucidated.

The generally accepted pathw ay

requires tw o enzymes, cis-A -trans-A -enoy 1-CoA isomerase (EC 5.3.3.8) and
3-hydroxy acy 1-CoA epimerase (EC 5.1.2.3), in addition to the norm al /3oxidation enzymes for the degradation of unsaturated fa tty acids (see Figure
2A ).84 The isomerase catalyzes the conversion of 3-cz's-enoyl-CoA intermediates
to the 2-trans isomer85 which can be fu rth er degraded by /3-oxidation.

The

epimerase catalyzes the epimerization of D-3-hydroxyacyl-CoA esters to the
corresponding L-hydroxy isomers84 , which can be completely degraded by the
norm al /3-oxidation enzymes.

Kunau and Dommes 86 have presented evidence

th a t the oxidation of 4-cz's-decenoyl-CoA follows a different pathw ay requiring
2,4-dienoyl-CoA reductase.

Acyl-CoA dehydrogenase II catalyzes the conver

sion of 4-a's-decenoy 1-CoA to 2-Trans,4-czs-decadienoy 1-CoA.

This compound

is reduced to 3-decenoyl-CoA by the NADPH-dependent 2,4-dienoyl-CoA
reductase86,87 ,(see Figure 2B).

The 3-decenoyl-CoA thus formed is isomer3
2
ized to 2-Trans-decenoy 1-CoA by the cz's-A -Trans-A -enoyl-CoA isomerase.
This later compound can be further degraded by the norm al enzymes of /3oxidation.

In addition, it was demonstrated th at czs-4-decenoyl-CoA is

degraded by beef liver mitochondria to octanoy 1-CoA w ithout the form ation of
cz's-2-octanoyl-CoA86 , an intermediate expected by the pathw ay of Stoffel and
Caesar.84
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More recently, Cuebas and Schulz88 dem onstrated th a t 2-trans,4-cisdecadienoyl-CoA, a m etabolite of linoleate, cannot be degraded by the pathw ay
proposed by Stoffel and Caesar.84 It was shown th a t while 2-transA-transdecadienoyl-CoA is rapidly degraded via /3-oxidation, a m ixture of 2-trans,4czs-decadienoy 1-CoA and 2-cis,4-cis-decadienoyl-CoA can not be degraded via
/3-oxidation by either ra t heart mitochondria or a reconstituted /3-oxidation
system even when the crotonase concentration was increased 10 fold over the
physiological level sufficient for the oxidation of 2-trans,4-trans-deeadienoylCoA.88 In addition, all three isomers of 2,4-decadienoyl-CoA were substrates
for the NADPH-dependent 2,4-dienoyl-CoA reductase.88 The pathw ay pro
posed by Cuebas and Schulz88 for the degradation of linoleic acid is presented
in Figure 2B.

The product of the reaction catalyzed by 2,4-dienoyl-CoA reduc

tase is 3-decenoyl-CoA86’ 89 which can be isomerized to 2 -trans-decenoy 1-CoA
by the cis-A -trans-A -enoyl-CoA isomerase.85 2-irans-Decenoyl-CoA can then
be completely degraded by the normal /3-oxidation pathw ay.
Q

O

Stoffel and Caesar84 have dem onstrated th a t the cis-A -trans-A -enoylCoA isomerase and the 3-hydroxyacyl-CoA epimerase are present in both rat
liver and ra t heart mitochondria in addition to the normal 3-oxidation
enzymes.

In our laboratory, we have only been able to show an extremely low

level of the epimerase activity in any mammalian heart tissue examined.90 It
was not clear w hether the epimerase activity observed in heart tissue could
support the level of linoleic acid degradation expected by this tissue.

In order

to fu rth er investigate this point, oxidation of palm itoy 1-CoA, oleoy 1-CoA and
linoleoyl-CoA were compared in ra t heart and rat liver mitochondria.

These

same mitochondrial preparations were examined for cis-A -ira/is-A -enoylCoA isomerase, 2,4-dienoyl-CoA reductase, and 3-hydroxyacyl-CoA epimerase
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activities by Mr. Chin-Hung C hu.91

Inhibition of Pyruvate Dehydrogenase Complex by Metabolites of 3Mercaptopropanoic Acid
The convulsant, 3-mercaptopropanoic acid, is believed to cause seizures by
interfering w ith

the metabolism of the inhibitory neurotransm itter, y -

am inobutyric acid (GABA), thereby causing a reduction in brain GABA concen
tration.92 3-Mercaptopropanoic acid has been shown to reversibly inhibit gluta
mate decarboxylase 93> 94>95 and to activate GABA aminotransferase.95 It has
also been suggested th a t 3-mercaptopropanoic acid disrupts energy metabolism
in ra t brain mitochondria, possibly by affecting the utilization or formation of
ATP.96 Sabbagh et al.,97 have shown 3-mercaptopropanoic acid to be a potent
inhibitor of fa tty acid oxidation in ra t heart mitochondria.

Apparently, meta

bolites of 3-mercaptopropanoic acid reversibly inhibit one or several of the |3oxidation enzymes.98

It has been dem onstrated th a t 3-mercaptopropanoic acid is activated in rat
heart m itochondria.

The 3-mercaptopropanoy 1-CoA thus formed is an

effective substrate for thiolase (EC 2.3.1.9 and EC 2.3.1.16).

When 3-

mercaptopropanoyl-CoA substitutes for CoASH in the thiolytic cleavage of
acetoacety 1-CoA, S-acetyl-3-mercaptopropanoy 1-CoA is formed (Figure 3).98

Since /3-oxidation is not a major pathw ay in brain15>16>99 , the observed
inhibition of this pathw ay in 3-mercaptopropanoic acid-treated rat heart m ito
chondria could not explain the onset of seizures in 3-mercaptopropanoic acidtreated rats.

Oxidation of glucose is the major pathw ay of energy production
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in the brain15>17>100 and inhibition of the key enzyme, pyruvate dehydro
genase, in this pathw ay w ould have a profound effect on energy metabolism in
this tissue.

In addition, there is a close dependence of acetylcholine synthesis

on the pyruvate dehydrogenase reaction.101,102,103 Since ketone bodies are oxi
dized by brain tissue in proportion to their concentration in the blood16,104 ,
the presence of acetoacety 1-CoA in the brain exposed to 3-mercaptopropanoic
acid may result in the production of S-acetyl-3-mercaptopropanoyl-CoA,
intram itochondrially.

In view of this information, the effects of 3-mercaptopropanoy 1-CoA and
S-acetyl-3-mercaptopropanoyl-CoA on pyruvate dehydrogenase complex and
its component enzymes were investigated.

In addition, the effects of S-aeetyl-

3-mercaptopropanoic acid and 3-mercaptopropanoic acid on pyruvate-supported
respiration in ra t heart and liver mitochondria were studied.

Aim of Research
Understanding the regulation of (8-oxidation in mammalian heart is the
major research aim of this laboratory.

Since fa tty acid activation and the

translocation of fa tty acyl groups into the mitochondria via the carnitine acyltransferase system are the first tw o com mitted steps of (3-oxidation, it is possi
ble th a t this pathw ay is controlled by the regulation of either the fa tty acylCoA synthetase or one of the CPT enzymes.

Hence, I have studied the effects

of metabolites and coenzymes on the activities of these tw o enzymes, especially
the effects of malony 1-CoA and its structural analogs on the activity of CPT A.
In addition, I have examined the possibility th a t the fa tty acyl-CoA synthetase
is regulated via phosphorylation-dephosphorylation.

The results of these
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studies gave no indication th a t fa tty acid oxidation in ra t heart mitochondria is
controlled via the regulation of either CPT or fa tty acyl-CoA synthetase.

Because of my experience in the isolation of m itochondria and measure
m ent of /3-oxidation, a new project was undertaken to dem onstrate th a t the
rate of oxidation of linoleoy 1-CoA in ra t heart m itochondria was too high to be
dependent on the low level of epimerase found in th a t organelle.

W hen I completed the first part of m y thesis research, other members of
our laboratory had dem onstrated th at 3-mercaptopropanoic iacid, a know n con
vulsive agent, is a potent inhibitor of fa tty acid oxidation in rat heart mitochndria.97 Since /3-oxidation is not a major pathw ay in brain15’ 16>99 , the
observed inhibition of this pathw ay could not explain the onset of seizures in
3-mercaptopropanoic acid-treated rats.

When it was demonstrated, in our

laboratory, th a t 3-mercaptopropanoic acid is activated and th a t the 3mercaptopropanoy 1-CoA th u s formed is an effective substrate for thiolase98 ,
the possibility th a t 3-mercaptopropanoy 1-CoA may act as a substrate or inhibi
to r of pyruvate dehydrogenase occurred to me and this study was then under
taken.

In addition, inhibition of the pyruvate dehydrogenase reaction by S-

acetyl-3-m ercapopropanoy 1-CoA (the product of the thiolase reaction) was
investigated.

Pyruvate dehydrogenase w as selected fo r this study because of

its key role in the energy metabolism of brain.
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EXPERIMENTAL PROCEDURES
Materials
Most organic chemicals and the pyruvate dehydrogenase complex were
purchased from Sigma Chemical Co.

NAD+, NADH, CoASH, and CoA deriva

tives not synthesized in our laboratory were purchased from P-L Biochemicals.
The enzyme, nagase, w as purchased from the Enzyme Development Corp., New
York, N.Y.

C itrate synthase was purchased from Boehringer-Mannheim Corp.

Radiolabelled compounds were purchased from New England Nuclear.
nin was purchased from Calbiochem.
from Aldrich Chemical Co.
Supelco, Inc.

Digito-

Diketene and DCPIP were purchased

Oleic acid and linoleic acid were purchased from

L-Carnitine and palm itoy 1-L-carnitine were the generous gifts of

Dr. K. Brendel, University of Arizona College of Medicine.

S-Acetyl-3-

mercaptopropanoic acid and bz's[2-carboxyethyl]disulfide were synthesized in
our laboratory by Dean Cuebas.

Pig heart 3-ketoacyl-CoA thiolase (EC

2.3.1.16) was purihed by Mr. Chin-Hung Chu according to published pro
cedures.105

Preparation of Rat Heart Mitochondria
Mitochondria were isolated from the hearts of adult male albino rats by
the following method.

The beating hearts were removed from tw o ether-

anesthetized rats and placed in ice-cold MST buffer106 (210 mM m annitol, 70
mM sucrose, 5 mM Tris, 1 mM EGTA, adjusted to pH 7.4 w ith HC1).

The

hearts were cut open, cleaned of blood vessels and w ashed free of blood in icecold MST buffer.

The hearts were finely minced.

The suspension was stirred
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continuously for 9 min a t 0°C w ith 6 mg of nagase, a general protease used to
soften the heart tissue by degrading some of the connective tissue protein.
This step was om itted if the mitochondria were to be used fo r the fa tty acylCoA synthetase reaction.
homogenization tube.

The resulting suspension was transferred to a glass

A fter dilution to approximately 30 ml in ice-cold MST

buffer, the suspension was homogenized by 5 strokes of a loose-fitting Teflon
pestle spinning at 750 rpm.

If nagase was used, the homogenate was centri

fuged at 20,000 rpm in an SS-34 rotor of a Sorvall Centrifuge fo r 7 min at
5°C.

The pellet was resuspended in about 30 m l of ice-cold MST buffer w ith a

rubber policeman and homogenized by one stroke of the glass-Teflon tissue
homogenizer.

The resulting suspension was centrifuged twice at 10,000 rpm in

an SS-34 rotor of a Sorvall Centrifuge for 7 min at 5°C.

When nagase was not

used, the homogenate was centrifuged at 10,000 rpm in an SS-34 rotor of a
Sorvall Centrifuge for 7 min at 5°C.

The pellet, each time, was resuspended in

about 30 ml ice-cold MST buffer w ith a rubber policeman and homogenized by
one stroke of the glass-Teflon tissue homogenizer.

The resulting suspension

was centrifuged at 2,300 rpm in an SS-34 rotor of a Sorvall Centrifuge for 5
min at 5°C.

The supernatant was decanted through tw o layers of cheesecloth

into 15 ml Corex tubes.

These tubes were centrifuged a t 8,000 rpm in an SS-

34 rotor of a Sorvall Centrifuge for 7 min at 5°C.

The mitochondrial pellets

were resuspended into a small volume of ice-cold MST buffer using a rubber
policeman.

Mitochondria prepared in this w ay were used fresh or stored

frozen at -80°C and used after thawing.

Integrity of the mitochondria isolated was assessed by determining the
respiratory control ratio (RCR) and NADH dehydrogenase activity by means of
oxygen consumption monitored at 25°C using a Clark oxygen electrode and
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Gilson Oxygraph.

The standard incubation m ixture contained in 2 ml, 0.11 M

KC1, 33 mM Tris, 2 mM KPz, 2 mM MgCl2> 0.1 mM EGTA, pH adjusted to 7.4
w ith HC1, and mitochondria (1 mg protein).

For measuring the RCR, the incu

bation m ixture also contained 1 m g/m l BSA, 0.5 mM Z-malate, and 30 /iM
palm itoy 1-Z-carnitine.
0.5 /im oles of ADP.

The state III respiration was initiated by the addition of
State IV respiration was taken as the rate of oxygen con

sum ption after ADP depletion.

The RCR is the ratio of state III to state IV

respiration.

The NADH dehydrogenase reaction was initiated by the addition of 0.5
/umoles of NADH to the standard incubation mixture.

A conversion factor of

1 nanoatom of oxygen consumed per nanomole of NADH oxidized was used.

Preparation of Rat Liver Mitochondria
Rat liver mitochondria were prepared from the livers of ad u lt male albino
rats by the following method.

The liver of one ether-anesthetized ra t was

removed and placed in ice-cold STE buffer (0.25 M sucrose, 5.0 mM Tris, 1 mM
EGTA, adjusted to pH 7.4 w ith HC1).

The liver was cleaned of large blood

vessels and washed free of blood in ice-cold STE buffer.

A fter finely mincing,

2-3 g of the tissue was transferred to a glass homogenization tube and diluted
to 35 m l in ice-cold STE buffer. This suspension was homogenized by 2 strokes
of a loose-fitting Teflon pestle spinning a t 750 rpm.
all of the tissue suspension was homogenized.

This was repeated until

The homogenate was centri

fuged at 2,300 rpm in an SS-34 rotor of a Sorvall Centrifuge for 10 min at
5°C.

The supernatant was decanted through tw o layers of cheesecloth into

fresh centrifuge tubes.

These tubes were centrifuged at 10,000 rpm in an SS-
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34 rotor of a Sorvall Centrifuge fo r 10 min a t 5°C.

The supernatants were

discarded and the w hite fluffy layers were washed off the mitochondrial pellets.
The pellets were resuspended into ice-cold STE buffer using a rubber policeman
and transferred to 15 ml Corex tubes.

These tubes were centrifuged at 9,000

rpm in an SS-34 rotor of a Sorvall Centrifuge fo r 10 min at 5°C.

The pellets

were again washed and resuspended and finally centrifuged at 8,000 rpm for 10
min.

The final mitochondrial pellets were resuspended into a sm all volume of

ice-cold STE buffer.

P re p a ra tio n o f Bovine H e art M ito ch o n d ria32

Bovine heart mitochondria were prepared from fresh bovine heart stored
several hours on ice.

The entire procedure was performed a t 4°C.

V entricular

tissue was cleaned of all fa t and connective tissue and cut into small pieces
which were passed through a meat grinder.

Portions of ground tissue (60 g)

were blended at high speed in a Waring blender for 45s in 500 ml Buffer A
(0.25 M sucrose, 5.0 mM HEPES, 0.25 mM EDTA, pH 7.7) followed by homo
genization in 60 ml aliquots for 30s w ith a Polytron tissue homogenizer set at
33% maximal speed.

The homogenized samples were pooled and centrifuged

for 15 min a t 500 x g, 15,000 x g, 500 x g, 11,000 x g, and 7,000 x g.

High

speed pellets were resuspended in isotonic buffer (0.25 M sucrose, 2.5 mM
HEPES, 0.25 mM EDTA, pH 7.5) by tw o strokes of a glass-Teflon tissue homoginizer w ith a loose-fitting plunger set at 750 rpm.

The 7,000 x g pellet was

resuspended in a small volume of isotonic buffer using a rubber policeman and
dispensed into test tubes which were stored a t -80°C.
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Preparation of Rat Heart Tissue Homogenate37
Homogenate was made from the hearts of adult male albino rats.

The

beating hearts were removed from ether-anesthetized rats and placed in ice-cold
buffer (180 mM KC1, 10 mM Tris, 10 mM EDTA, 0.5 % (w /v ) BSA, pH 7.6).
The atria and blood vessels were cleaned from the ventricular tissue, which was
then washed free of blood in fresh buffer.

The tissue was minced, then

transferred to 6 m l ice-cold buffer in a 30 ml centrifuge tube and homogenized
on ice w ith a Polytron tissue homogenizer w ith rheostat at 33% maximal speed
for tw o 5-s periods.

The homogenate was diluted in ice-cold buffer and homo

genized in a glass-Teflon homogenizer w ith a loose-fitting pestle.

Subcellular Fractionation of Rat Heart Tissue

M ethod I

Hearts were obtained and minced as described on page 20.

The finely

minced hearts were transferred to a glass homogenization tube and diluted to
approxim ately 30 ml in ice-cold MST buffer.

The suspension was homogenized

by 5 strokes of a loose-fitting Teflon pestle spinning a t 750 rpm.

The homo

genate was centrifuged at 2,300 rpm in an SS-34 rotor of a Sorvall Centrifuge
fo r 5 min a t 5°C.

A portion of the supernatant was retained as the whole

heart homogenate. The remainder of the supernatant was centrifuged at
44,000 rpm in a Type-50 rotor of a Spinco Ultracentrifuge for 1 h r at 5°C.
The high-speed supernatant was retained as the cytoplasmic fraction.

The

high-speed pellet was resuspended in a small volume of MST buffer and
retained as the extracytoplasm al fraction.

The three fractions were stored
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overnight at -20°C.

A fter thawing, the whole heart homogenate and the

extracytoplasm ic fraction were sonicated vising the microtip of a probe-type
sonicator for 5 x 5 sec at 4°C.

The sonicated fractions were centrifuged at

44,000 rpm in a Type-50 rotor of a Spinco Ultracentrifuge fo r 1 h r a t 5°C.
The pellet w as discarded.

Method I I

A homogenate of the rat heart tissue was obtained as in Method I.

The

homogenate was centrifuged at 10,000 rpm in an SS-34 rotor of a Sorvall Cen
trifuge for 7 min at 5°C.
fraction.

The supernatant was retained as the cytoplasmic

The pellet was resuspended in about 30 ml ice-cold MST buffer w ith

a rubber policeman and homogenized by one stroke of a glass-Teflon tissue
homogenizer.

The resulting suspension was centrifuged at 2,300 rpm in an

SS-34 rotor of a Sorvall Centrifuge for 5 min a t 5°C.

The supernatant was

decanted through tw o layers of cheesecloth into 15 ml Corex tubes.

These

tubes were centrifuged at 8,000 rpm in an SS-34 rotor of a Sorvall Centrifuge
fo r 7 min at 5°C.

The mitochondrial pellets were resuspended into a small

volume of ice-cold MST buffer using a rubber policeman.

The mitochondrial

fraction was sonicated using the microtip of a probe-type sonicator for 5 x 5
sec.

Both the sonicated mitochondrial fraction and the cytoplasmic fraction

were centrifuged at 44,000 rpm in a Type-50 rotor of a Spinco Ultracentrifuge
fo r 1 hr an 5°C.

The pellets were discarded.
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Measurement of Protein Concentration
Protein concentration w as determined by either the Biuret M ethod107 or
the Low ry M ethod108 using BSA as standard.

Measurement, of Oxygen Uptake by Mitochondria
Oxygen consumption w as m onitored at 25°C by means of a C lark oxygen
electrode and Gilson Oxygraph.

The standard incubation m ixture for ra t heart

m itochondria contained 0.11 M KC1, 33 mM Tris (pH 7.4), 2 mM KP;, 2 mM
MgCl2> 0.1 mM EGTA, and m itochondria (O.r mg protein/m l).

The standard

incubation m ixture for ra t liver mitochondria contained 0.1 M KC1, 20 mM
Tris (pH 7.4), 4 mM KP; (pH 7.4), 4 mM MgCl2, 0.1 mM EGTA, and m ito
chondria (1 mg protein/m l).

When palmitoyl-Z-carnitine (30 /xM) was used as

substrate, 14.7 /xM BSA was included in the incubation mixture.

When fa tty

acyl-CoA (15 /xM) was used as substrate, 14.7 /xM BSA, 0.5 mM L-malate, and
13 mM /-carnitine was included in the incubation m ixture.

In addition, either

0.5 mM m alate or 5 mM a-ketoglutarate, was also included in the incubation
m ixture.

A fter preincubation of the m ixture for about 1 min, the reaction

w as started by the addition of ADP (final concentration, 1 mM) and substrate.
Respiratory Control Ratios (RCR) were measured using 30 /txM palm itoy 1-/cam itine as substrate, in the absence of carnitine.

Preparation of Malonyl-CoA
Reduced coenzyme A, Li salt (12.5 mg), S-m alonyl-N -capryl cysteamine
(17.4 mg), and sodium bicarbonate (42 mg) were placed in a test tube to which
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was added 1 ml of distilled w ater.

This w as left at room tem perature for 1

hr, then refluxed w ith ether for 30 min.

The pH of the solution was adjusted

to 1.0 w ith 2 N H2S 0 4. The solution w as extracted w ith ether for 30 min and
adjusted to pH 5.0 w ith 1.0 N KOH.

Residual ether w as removed under a

stream of nitrogen.

Preparation of Acetoacetyl-CoA 109
Reduced CoA, Li salt (8 mg), and 3 fxl of diketene were added to 1 ml of
0.1 M potassium bicarbonate.

This solution was stirred under a stream of

nitrogen for 20 min a t room temperature.

The pH w as adjusted to 3-4 w ith

concentrated HC1.

Preparation of Succinyl-CoA 110
Reduced CoA, Li salt (7 mg), was dissolved in 1 m l of ice-cold distilled
w ater.

Succinic anhydride (85.38 mg) w as added and the pH adjusted to 8.0

w ith 71.66 mg sodium bicarbonate.
30 min w ith frequent shaking.

The m ixture was kept in an ice bath for

The pH was brought to 2.0. The resulting

solution was stored at -20°C.

For suceinyl-CoA solution devoid of CoASH the following procedure was
performed at 0°C under nitrogen.

Potassium bicarbonate (25 mg) was dis

solved in 1 m l of ice-cold distilled w ater.

The solution w as evacuated w ith a

stream of nitrogen prior to addition of 7 mg of reduced CoA, Li salt.

Succinic

anhydride (20 mg) was dissolved in 3 m l of dry THF and the resulting solu
tion was added (6-8 drops at a tim e) to the CoASH solution u n til no yellow
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color was observed when a drop of the solution was added to a drop of
E llm an’s reagent.111 The pH of th e solution was brought to 1.0 and the THF
removed by rotary evaporation under reduced pressure.

The pH w as brought

to 2.0 and the resulting solution w as stored a t -20°C.

Preparation o f Oleoyl-CoA and Linoleoyl-CoA
Oleoyl-CoA and linoleoyl-CoA w ere prepared w ith th e assistance of Dean
Cuebas by the mixed anhydride method of Goldman and Vagelos.112 During
this procedure, all operations were carried ou t under nitrogen.

The final aque

ous solutions were stored under nitrogen in sealed ampules a t -76°C.

Preparation of 3-Mercaptopropanoyl-CoA
The mixed anhydride method of Goldman and Vagelos112 w as used to
synthesize the CoA derivatives of M s-[2-carboxyethyl]-disulfide.

The products

form ed were separated on a DEAE cellulose column by gradient elution w ith 0
to

0.3

M

LiCl,

pH

4.0.

The

fractions

containing

2-carboxyethyl-

disulfidepropanoy 1-CoA were identified spectrophotom etrically in a Gilford
Spectrophotometer by measuring absorbance at 260 nm and 235 nm.

The

appropriate fractions were pooled and concentrated to 3.3 ml on an Amicon
Diaflo U ltrafiltration membrane, YC 05, using 50 psi N2> The p u rity of the
product as determined by assessing the concentration of both adenosine and
thioester.

That of adenosine was measured spectrophotom etrically at an

absorbance of 260 nm; th a t of thioester w as measured by the m ethod of Ellm an.111 Theoretically, the ratio of adenosine to thioester bond should be 1:1.
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This solution was acidified to pH 1-2 w ith HC1 and purged w ith nitrogen.
The disulfide linkage was reduoed w ith 40-60 mg zinc d u st w ith constant vortexing under nitrogen until the Ellm an Test 111 revealed th a t the reaction had
gone to completion.

The solution was filtered to remove excess zinc dust, and

applied to a DEAE cellulose column.

Gradient elution w ith 0 to 0.3 M LiCl,

pH 4.0, th a t had been purged w ith N2 was perform ed.
ing

3-mercaptopropanoy 1-CoA

were

measuring the absorbance a t 260 nm.

identified

The fractions contain

spectrophotom etrically

by

The appropriate fractions were pooled

and concentrated to approxim ately 3.5 ml on an Amicon Diaflo U ltrafiltration
membrane, YC 05, using 50 psi N2< The p u rity of the product was determined
by assessing the concentration of adenosine, free su lfh y d ry l group and thioes
ter.

T hat of adenosine was measured spectrophotom etrically at 260 nm; that

of free sulfh y d ry l group and thioester were measured by the method of Ell
man.111 Theoretically, the ratio of adenosine to free su lfy d ry l group, to thioes
ter bond should be 1:1:1.

By this method, the solution was determined to con

tain 88% 3-mercaptopropanoy 1-CoA and 12% dimerized 3-m ercaptopropanoylCoA.

The product was purged w ith nitrogen and stored a t -80°C.

Prior to

use, the solution was thaw ed and the concentration reassessed.

P re p a ra tio n o f S-A cetyl-3-M ercaptopropanoyl-C oA

S-Acetyl-3-mercaptopropanoyl-CoA was synthesized by th e mixed anhy
dride method of Goldman and Vagelos.112 The crude product th u s form ed was
purified on a DEAE cellulose column by gradient elution w ith 0 to 0.3 M LiCl,
pH 4.0.

The fractions containing S-acetyl-3-mercaptopropanoyl-CoA were

identified spectrophotom etrically by measuring absorbance at 260 nm and 235
nm.

The appropriate fractions were pooled and concentrated to 3.5 ml on an
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Amicon Diaflo U ltrafiltration membrane, YC 05, using 50 psi N2.
of the product w as determ ined by tw o methods.

The purity

Spectrophotom etrically, the

concentration of adenosine w as determined by measuring the absorbance at 260
nm, and the concentration of thioester was measured by the m ethod of Ellm an.111 Theoretically, the ratio of adenosine to thioester bond should be 1:2.
The compound w as alw ays found to be greater than 99% pure by this method.
HPLC was also used to assess p u rity of the product, using a W aters Microbondapak C l8 column and eluting w ith a gradient of 0.05 M amm onium phos
phate buffer, pH 5.5, containing 15-30% m ethanol, in 3 min a t a rate of 1
m l/m in.

This method revealed three contam inants, w ith the major com

ponent, S-acetyl-3-mercaptopropanoyl-CoA alw ays representing at least 88%
of the CoA-containing material.

Preparation of d,/-Dihydrolipoamide
Dihydrolipoamide was synthesized by the reduction of d,Z-lipoamide by
the method of Reed et al..113 A suspension of 200 mg d,Z-lipoamide in 5 ml
m ethanol/w ater, 4/1 (v /v ), was stirred at 0°C.

A solution of 200 mg sodium

borohydride in 1 ml w ater was cooled and added to the lipoamide suspension
w hile stirring.
colorless.

The reaction m ixture was stirred until it became clear and

The solution was acidified w ith HC1 and the m ethanol was eva

porated under a stream of nitrogen.

The aqueous solution remaining was

extracted 5 times w ith 15 ml of chloroform.

The resulting chloroform solu

tion was evaporated to dryness under reduced pressure.

The residue was

recrystallized from a solution of petroleum ether and acetone to yield 46.91 mg
of w hite plates; m.p. 63.5-65.5°C.
yielded

8.44

mM

free

A solution of 4.49 mM dihydrolipoam ide

su lfh y d ry l

group

based

on

the

Ellm an’s
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determ ination.111

Ellman’s Determination111 of the Concentration of Coenzyme A Deriva
tives
H ydroxylam ine w ill cleave the thioester bond of a coenzyme A derivative.
The resulting free CoASH w ill react w ith 5,5’-dithio-Ms-C2-nitrobenzoic acid)
to produce 5-thio-2-nitrobenzoate which absorbs light strongly at 412 nm w ith
a m olar extinction coefficient of 13,600 cm—1M—1 at pH 8.0.114

A sm all aliquot of the derivative (5-20 /il) was placed in a cuvette w ith
20 ytil of 2 M hydroxylamine, pH 7.0.
tem perature for 5 min.

This was allowed to stand at room

To this was added 10 /u.1 of Ellm an’s reagent, 300

/j . \

of 0.1 M potassium phosphate buffer (pH 8.0), and distilled w ater to a total
volume of 1 ml.
ter.

Absorbance at 412 nm was read in a Gilson Spectrophotome

The value obtained was corrected for free CoASH in the solution by per

form ing the Ellm an’s determ ination w ithout the addition of hydroxylamine.

A ssay f o r Palm itoyl-C oA S y n th e ta se A c tiv ity

A ctivity was measured based on the rate of production of [U -14Clpalm itoy 1-CoA from [U-14C]-palm itate.6 The assay system contained 0.1 M
Tris, 4 mM MgCl2, 5 mM reduced glutathione, 2 mM KCN, 5 mM malonate, 5
mM ATP, 0.15 mM CoASH, 0.02 mM BSA, and 0.1 mM [U-14C]-palm itate
(0.45 m Ci/m m ole) in a volume of 1 ml.
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The reaction was started by the addition of 0.25-0.30 mg of protein.

The

samples were incubated in a 37°C w ater bath and the reaction w as stopped by
the addition of 4 m l of Dole reagent 115 (isopropyl alcohol/n-heptane/1 N
H2S 0 4, 40/10/1, v /v /v ).
tion of protein.

Control tubes had Dole reagent added prior to addi

To each tube, 1.4 ml of distilled w ater and 2.4 m l of heptane

were added. The sample w as vortexed and centrifuged. The upper layer, con
taining the unreacted palm itate, was removed.
washed four times w ith 2.4 m l of heptane.

The low er aqueous layer was

An aliquot of the low er aqueous

layer, containing [14C]-palm itoy 1-CoA, was placed in 10 m l of Bray’s solution
and assayed for radioactivity by liquid scintillation counting in a Beckman
Scintillation Counter.

S pectro p h o to m etric A ssay f o r C a rn itin e P a lm ito y ltra n sfe ra s e A c tiv ity 116

The assay was based on measuring the initial rates of RSH form ation using
the DTNB reaction.

The product, 5-thio-2-nitrobenzoate, absorbs light

strongly at 412 nm w ith a m olar extinction coefficient of 13,600 cm- 1 M—1 at
pH 8.O.114

The assay system contained 116 mM Tris-Cl (pH 8.0), 0.09 % Triton X100, 0.035 mM palm itoy 1-CoA, 0.11 mM DTNB, 1.1 mM Z-camitine, 1.1 mM
EDTA* , in a volume of 1 ml.

The reaction was started by the addition of protein.
nm was monitored over a tim e period of 2-5 min.

Absorbance at 412

The rate of free RSH

EDTA w as demonstrated to be unnecessary for maximal activity and w as om itted in several
assays.
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form ation by competing reactions was assayed by omission of carnitine from
the assay mixture.

This value was subtracted from th a t determ ined in the

carnitine-containing mixture in order to determine the rate of CPT-generated
CoASH formation.

Radiochemical Assay for Carnitine Palmitoyltransferase A ctivity77’ 78
Rat heart mitochondrial protein (0.05 mg) was preincubated a t room tem 
perature for 2 min in 1 ml containing 210 mM sucrose, 30 mM KC1, 50 mM
Tris-HCl or MOPS-KOH, pH 7.4, 1 mM EGTA, BSA (1.3 m g/m l), 40 mmoles of
Z-carnitine containing 0.6-1.0 ^Ci cZ,Z-[Me-14C]-carnitine or 1.1 /tzCi <2,Z-[Me3H]-camitine and 40 /zM palmitoyl-CoA.

The reaction was term inated after

2-4 min w ith 1 ml of ice-cold 1.2 M HC1 followed by 2 ml of w ater-saturated
butanol.

A fter vortexing and brief centrifugation, the butanol layer was

washed w ith 5 ml of butanol-saturated w ater.

An aliquot of the butanol

layer was taken for liquid scintillation counting in 5 ml of Scintiverse II
(Fisher Scientific) using a Beckman Liquid Scintillation Counter.

Hydrolysis of CoASH Derivatives Under Assay Conditions
The assay was based on measuring the rates of RSH form ation using the
5,5 ’-dithio-6A-(2-nitrobenzoic acid) reaction as described on page 31, under the
conditions used in the radiochemical assay fo r carnitine palm itoyltransferase.

Rat heart mitochondria (0.05 mg) was added to 1 ml containing 210 mM
sucrose, 30 mM KC1, 50 mM Tris-HCl or MOPS-KOH (pH 7.4), 1 mM EGTA,
1.3 m g/m l BSA, 100 /zM CoASH derivative (palmitoyl-CoA was om itted).
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Absorbance at 412 nm was measured fo r 2 min.

/-C arnitine (0.4 yumoles) was

added and the absorbance at 412 nm was measured fo r at least 2 min.

Initial

rates of hydrolysis of CoASH derivatives were determined for the preincuba
tion period (w ithout carnitine) and the reaction period (w ith carnitine).

Separation of Palmitoyl-CoA Synthetase A ctivity from CPT A ctivity
This procedure was based on the m ethod described117 fo r th e separation of
the outer mitochondrial membrane from the " m itoplast".

A stock solution of 1.0% digitonin in isotonic beef heart m itochondria iso
lation buffer was prepared by dissolving the digitonin in hot (alm ost boiling)
buffer.
solution.

After cooling to room tem perature, BSA (50 m g/m l) was added to the
A volume of beef heart mitochondria (100 m g/m l protein) was

placed in a pre-cooled vial on ice, to which an equal volum e of th e digitonin
stock solution was added.
stirrer for 15 min on ice.

The m ixture was stirred gently w ith a magnetic
The solution was diluted w ith 3 volumes of buffer

and centrifuged at 9,000 x g in the SS-34 rotor of the Sorvall Centrifuge at 4°C
for 10 min.

The supernatant, which should contain the outer membrane vesi

cles and intermembrane components117 , was retained.

The pellet was brought

to one half the original volume w ith buffer and centrifuged a t 9,000 x g in the
SS-34 rotor of the Sorvall Centrifuge a t 4°C for 10 min.

The resulting super

n atan t was combined w ith the first supernatant, and th e pellet was discarded.

The supernatant obtained was treated in one of tw o w ays.

Either the

protein was precipitated out of solution by ammonium sulfate precipitation at
4°C followed by centrifugation, or the protein was brought ou t of solution by
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ultracentrifugation at 144,000 x g for 1 h r in a Spinco ultracentrifuge.

The

pellets were resuspended in a sm all am ount of buffer and stored a t -80°C.

Assay f o r Succinate T h io k in ase (EC 6.2.1.4 )118

A ctivity was measured based on the rate of production of succinyl-CoA
from succinate and reduced CoASH.

Tris-succinate, pH 7.4, was prepared as a

solution containing 0.1 M succinate and 0.22 M Tris.

The assay system , 1 ml

in volume, contained 0.11 M Tris, 0.05 M succinate, 0.01 M MgCl2> 0.10 mM
GTP, and 0.10 mM CoASH.

The reaction was initiated by the addition of pro

tein. The reactions were allow ed to proceed at room tem perature for 5, 20, and
40 min, at which times a 250 fx1 aliquot was removed to 25 fil of 1.2 N HC1 to
stop the reaction.

Controls were prepared by adding the appropriate am ount

of protein to a 250 fx\ assay system which had already been acidified.

A fter

10 min at pH 1, the solutions were brought to pH 3 w ith 10 fil of 1 M KOH.

W hen the assay was repeated on subcellular fractions obtained by Method
II, it was performed in a volume of 250 fil containing, in addition to the usual
components, 0.10 mM ATP.

The reaction was stopped after 5 min by the

addition of 40 /jlI of 1.2 N HC1.

A fter 10 min a t pH 1, the solutions were

brought to pH 3 w ith 15 /d of 1 M KOH.

Succinyl-CoA content of each solution was determined by reversed-phase
HPLC using a W aters Microbondapak C18 column w ith absorbance detection at
254 nm.

A gradient elution system was employed using 5-9% m ethanol in 0.5

M ammonium phosphate buffer, pH 5.5, and a rate of 1.5 m l/m in.
w as measured.

Peak area
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Assay for Citrate Synthase (EC 4.1.3.7)119
The assay was based on measuring the initial rates of RSH form ation using
the 5,5’-dithio-hi's-(2-nitrobenzoic acid) reaction of Ellm an.111

The assay system , 1 m l in volume, contained 0.1M Tris-HCl (pH 8.1), 0.1
mM DTNB, 0.3 mM acetyl-CoA, and 0.5 mM oxaloacetate.

The enzyme source

was added to the solution containing Tris, DTNB, and acetyl-CoA.
tion was initiated by addition of oxaloacetate.

The reac

Absorbance at 412 nm was

m onitored over a time period of 2-5 min.

Assay for Enoyl-CoA Hydratase (EC 4.2.1.17)120
The assay m ixture contained, in a volume of 1 ml, 0.35 M Tris-HCl (pH
7.4), and 85 /jlM crotonyl-CoA.
enzyme source.

The reaction was initiated by the addition of

Absorbance change at 280 nm was measured in a Gilford Spec

trophotom eter.

Assay for 3-Hydroxyacyl-CoA Dehydrogenase (EC 1.1.1.35)116
Oxidation of NADH was measured spectrophotometrically a t 340 nm in a
Gilford Spectrophotometer.

The assay m ixture contained, in a volume of 1 ml,

0.35 M Tris-HCl (pH 7.0), 0.1 mM NADH, and 50 /ttM acetoacetyl-CoA.
reaction was initiated by addition of enzyme source.

The
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A ctivity o f Pyruvate Dehydrogenase Complex
Pyruvate dehydrogenase complex was assayed spectrophotom etrically at
30°C as described by Pettit and Reed.121 The assay m ixture contained, in a
volume of 1 ml, 50 mM KP/ CpH 7.4), 1.0 mM MgCl2, 2.5 mM TPP, 65 yuM
CoASH, 16 yuM dithiothreitol* , 2.0 mM sodium pyruvate (Sigma type II), 2.5
mM NAD+, and the enzyme.

Absorbance changes were m onitored at 340 nm

in a Gilford Spectophotometer.

A ctivity of Pyruvate Dehydrogenase (EC 1.2.4.1)
Pyruvate dehydrogenase w as measured spectrophotom etrically by the
method

of Lowe et al.122 , in an assay involving reduction of 2,6-

dichlorophenolindophenol.

The reaction m ixture contained, in a volume of 1

m l, 0.1 M KP; (pH 7.0), 100 yuM or 50 yuM dichlorophenolindophenol, 0.2 mM
TPP, 1 mM MgCl2, 50 mM sodium pyruvate (Sigma type II), and the enzyme.
The reduction of 2,6-dichlorophenolindophenol was measured spectropho
tom etrically at 600 nm in a G ilford Spectrophotometer.

This enzyme was also measured spectrophotom etrically in an assay
involving the reduction of ferricyanide.

The reaction m ixture contained, in a

volume of 1 ml, 0.1 M KPi (pH 6.5), 18 or 1.8 mM potassium ferricyanide,
0.14 mM TPP, 0.71 mM CaCl2, 36 mM sodium pyruvate (Sigma type II), 1.4
m g/m l BSA, and the enzyme.

The reduction of ferricyanide was measured

spectrophotom etrically at 410 nm in a Gilford Spectrophotometer.123
D ithiothreitol w as dem onstrated to be unnecessary for m aximal activity and w as therefore
om itted in many o f the assays.
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A ctivity of Pyruvate Dehydrogenase - Lipoate Acetyl Transferase
The combined pyruvate dehydrogenase - lipoate acetyl transferase activity
was assayed by measuring the am ount of acetyl-CoA produced.

This was

quantitated by converting it to citrate and CoASH.

pyruvate + lipoamide + CoA SH

^ acetyl-CoA + dihydrolipoam ide

acetyl-CoA + oxaloacetate -lu a te synth-~i> citrate + CoASH

The reaction m ixture contained, in a volume of 2.5 ml, 50 mM Tris-HCl (pH
7.4), 1.0 mM MgCl2, 0.2 mM TPP, 65 /iM CoASH, 2.0 mM sodium pyruvate
(Sigma type II), 0.4 mM lipoamide, and the enzyme.

The reaction was stopped

at various time intervals by addition of a 0.5 m l aliquot of the reaction mix
ture to 0.5 ml of the citrate synthase reaction m ixture containing 150 mM
Tris-HCl (pH 8.1), 0.8 mM DTNB, and the citrate synthase.

The reaction was

initiated by the addition of 5.0 /m o le s of oxaloacetate and allowed to go to
completion.

The absorbance at 412 nm, an absorbance maxima fo r 5-thio-2-

nitrobenzoate which is released by the reaction of DTNB w ith free su lfh y d ry l
groups114 , was measured spectrophotom etrically in a Gilford Spectrophotome
te r prior to the addition of oxaloacetate and after the reaction had gone to com
pletion.

The difference between the tw o values was used to determ ine the

am ount of acetyl-CoA produced.
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A ctivity of Lipoamide Dehydrogenase
Lipoamide dehydrogenase activity was assayed in both the forw ard and
reverse direction by the m ethod of Hayakawa et al..124 For the forw ard direc
tion, the reaction m ixture contained 50 mM KP/ (pH 6.5), 0.1 mM NAD+, 0.4
mM dihydrolipoamide, 1.25 mM EDTA, and the enzyme, in a final volum e of 1
ml.

For the reverse direction, the reaction m ixture contained 50 mM KP/ (pH

6.5), 0.1 mM NADH, 0.4 mM lipoamide, 1.25 mM EDTA, and the enzyme, in a
final volume of 1 ml.

The disappearance and form ation of NADH were meas

ured spectrophotom etrically a t 340 nm in a G ilford Spectrophotometer.

Rapid Gel Filtration of Pyruvate Dehydrogenase Complex
Rapid gel filtration of the enzyme w as perform ed by applying 0.1 m l of
sample to a 1 ml Sephadex G-50 column w hich had been w ashed w ith 50 mM
KP/ buffer (pH 7.4) containing BSA (10 m g/m l) and from which th e void
volum e had been removed by centrifugation.

The eluate w as quickly collected

by centrifugation of the charged column for 2 min in a clinical centrifuge.
Samples were prepared, each containing in 0.2 m l, pyruvate dehydrogenase
(0.085 mg protein), 50 mM KP/ (pH 7.56), 1 mM MgCl2, 0.2 mM TPP, 66.5
/zm CoASH, 2 mM sodium pyru v ate (Sigma Type II), ±235.25 yczM S-acetyl-3mercaptopropanoyl-CoA, and incubated at room tem perature for 15 min.

Just

prior to centrifugation, BSA w as added to the sample to give a final concentra
tion of 0.3% BSA.

Aliquots of 20 /zl were assayed im m ediately w hile 100 /zl

of each sample was subjected to rapid gel filtration and then assayed for p y ru 
vate dehydrogenase activity.
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NADH-Dependent Acetylation of the Pyruvate Dehydrogenase Complex
The NADH-dependent acetylation of the pyruvate dehydrogenase complex
by [ l - 14C]-acetyl-CoA, was perform ed by the method of Collins and Reed.125

The reaction m ixture contained 0.2 - 0.22 mg pyruvate dehydrogenase
complex, 50 mM KPi, pH 7.0, Im M MgCl2> 0.2 mM TPP, 0.1 mM NADH, and
± S-acetyl-3-m ercaptopropanoyl-CoA.

This w as preincubated at room tem 

perature for 3 min prior to initiation of the reaction w ith 10/d of 6.25 mM [114C]-acetyl-CoA, 10 /cCi/ml, to bring the volume of the reaction m ixture to a
total of 250 /d .

Aliquots of 50 /ul were removed from the reaction m ixture at

5 min and 10 min and applied to squares (2x2 cm) of W hatm an No. 3MM
filter paper.

The papers were w ashed four times w ith 20 ml of ice-oold 10%

trichloroacetic acid w ith shaking for 10 min each time.

This was followed by

washing twice w ith 20 m l of ice-cold ethanol w ith shaking for 5 min, followed
by washing twice w ith 20 m l of ice-cold ether at room tem perature w ith shak
ing.

The papers were placed in 5 m l of Scintiverse II (Fisher Scientific) and

counted in a Beckman Scintillation Counter.

Effect of Enzym atically Prepared S-Acetyl-3-Mercaptopropanoyl-CoA on
the Pyruvate Dehydrogenase Complex
S-Acetyl-3-m ercaptopropanoyl-CoA was synthesized enzym atically using
3-mercaptopropanoyl-CoA as a su b strate fo r 3-ketoacyl-CoA thiolase.

V ary

ing concentrations of 3-m ercaptopropanoyl-CoA w ere added to a cuvette con
taining 33 /cM acetoacetyl-CoA, 1.0 mM MgCl2, BSA (0.1 m g/m l), 0.1 M
Tris-HCl, pH 8.0, and thiolase (33 m U /m l) in 1 ml.

The reaction was
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observed to go close to completion by monitoring the change in absorbance at
303 nm.

The reaction was fu rth er pulled to completion by conversion of the

acetyl-CoA to citrate, catalyzed by citrate synthase.

The resulting solution containing S-acetyl-3-mercaptopropanoyl-CoA was
made to contain 2.5 mM TPP, 130 /zM CoASH, 2.0 mM sodium pyruvate
(Sigma Type II), and the pyruvate dehydrogenase enzyme.

A fter 3 min incu

bation at 30°C, the reaction was initiated by th e addition of 10 /zl of 0.25 M
NAD+ and the change in absorbance at 340 nm was measured using a Gilford
Spectrophotometer.

The control reaction included CoASH instead of 3-mercaptopropanoylCoA in the thiolase reaction.

In assessing the effects of 3-mercaptopropanoyl-CoA and chemically syn
thesized S-acetyl-3-mercaptopropanoyl-CoA on pyruvate dehydrogenase under
these conditions, they were added to the assay m ixture subsequent to the
citrate synthase reaction.

- 42 -

RESULTS AND DISCUSSION

Regulation of Fatty Acyl-CoA Synthetase and Carnitine Palm itoyl
transferase
As indicated in Table 1, likely effectors of palm itoyl-CoA synthetase
activity were tested at levels which are likely to be above their concentrations
in heart cytosol.

Ketone bodies, glycolytic interm ediates, NAD+, and NADH

had no effect on the enzyme.
activity by 41%.

5 mM ADP was found to inhibit synthetase

This was the same level of inhibition found for the rat liver

microsomal enzyme.42 Octanoylcarnitine, at a concentration of 1 mM, was
found to have no effect on the enzyme.

Palm itoylcarnitine was shown to have a significant effect on the activity of
palm itoyl-CoA synthetase (Table 2).
the enzyme by 45%.

Palm itoylcarnitine at 1 mM inhibited

As shown in Table 2 and Figure 4, raising levels of this

carnitine derivative from 0 to 2 mM had an increasingly inhibitory effect on the
enzyme.

Inhibition of palm itoyl-CoA synthetase by palm itoylcarnitine never

exceeded 45%.

Carnitine palm itoyltransferase activity in ra t heart mitochondria was
determined to fall in the range of 11.4 to 15.0 nm ol/m in/m g protein, depend
ing on the particular preparation.

Since this activity was comparable to or in

excess of the activity of the synthetase, it was considered th a t the CPT enzyme,
acting in the reverse direction, could be masking the inhibitory effect by
decreasing the effective concentration of palm itoy 1-carnitine in the assay mix
ture.

A lternatively, the same reaction could serve to increase the concentration
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of palmitoyl-CoA, which itself is an inhibitor of the synthetase.37

An attem pt was made to separate palmitoyl-CoA synthetase activity from
carnitine palm itoyltransferase activity of beef heart mitochondria by digitonin
fractionation.

Digitonin selectively removes the outer membrane of liver m ito

chondria, w ithout an apparent effect on the inner mitochondrial membrane.117
Because palmitoyl-CoA synthetase is located on the outer membrane4’5 and
CPT on the inner membrane25’ 26,27,28,29 , it was expected th a t these activities
could be separated by the digitonin fractionation procedure.

It was fu rth er

expected that the palmitoyl-CoA synthetase activity w ould be recovered in the
"outer membrane plus intermembrane" fraction and th a t this fraction w ould be
devoid of CPT activity.

As shown in Table 3, the results were not as expected.

Significant CPT activity was recovered in the "outer membrane" fraction.

This

is probably due to the fact th a t carnitine palm itoyltransferase A is loosely
associated w ith the outer surface of the inner mitochondrial membrane and was
easily removed by the perturbation.

Other researchers have also had

difficulties separating these tw o activities by membrane fractionation tech
niques.126’ 127 In fact, Bergstrom and Reitz30 dem onstrated th a t 25% of rat
liver mitochondrial CPT was easily released and solubilized by digitonin treat
ment.

Hoppel and Tomec27 used this technique to release CPT A from the

membrane.

In addition, this technique was developed for use w ith liver mito

chondria and it is not known if it is effective w ith heart mitochondria.

The possibility of covalent modification of the palmitoyl-CoA synthetase
by

phosphorylation-dephosphorylation

was

investigated.

Since

such

modification w ould be caused by a cytosolic protein such as protein kinase or
protein

phosphatase,

assays

were performed

using

whole

heart

tissue
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homogenate.

Prior to assay for palm itoyl-CoA synthetase activity, th e homo-

genate was preincubated at 25°C w ith compounds know n to regulate the activi
ties of various protein kinases or phosphatases.

Assays were performed w ith

and w ithout the potential effectors included in the assay m ixture.

A num ber of substrate proteins for Ca

2+

-dependent protein kinases have

been identified in the cytosolic and m itochondrial fractions of guinea pig
heart.128 These protein kinases were show n to be either phospholipid- or
calmodulin-sensitive.

Phosphorylation of one m itochondrial protein w as aug

mented by calmodulin in the presence or absence of added CaCl2>128 In addi
tion, phosphorylation of a cytosolic and a mitochondrial protein catalyzed by a
calmodulin-sensitive Ca2+-dependent protein kinase was inhibited by palmi
toylcarnitine.128

ATP has been shown to stim ulate phosphorylation of acetyl-CoA carboxy
lase via a protein kinase, in the absence of additional regulators.129- 130 Many
protein kinases are cyclic-AM P-dependent131>132 , sometimes requiring preincu
bation w ith cyclic-AMP prior to the addition of ATP.133 Fluoride, a know n
inhibitor of phosphatase,129 was also examined.

The results, shown in Table 4, indicate th a t regulators of protein kinases
or protein phosphatases may cause either a slight stim ulation or a slight inhibi
tion of palmitoyl-CoA synthetase.

These effects, however, are too sm all to

indicate regulation of the enzyme via phosphorylation-dephosphorylation.

As indicated in Table 5, likely effectors of CPT activity were tested at lev
els equal to or greater than their maximal concentrations in heart cytosol.

- 45 -

Pyruvate, lactate, NAD+, and NADH were shown to have an insignificant, if
slightly stim ulatory, effect on the enzyme.

j3-H ydroxybutyrate, fructose-1,6-

diphosphate, ADP, ATP, acetyl-cam itine, and octanoyl-carnitine were shown to
be slightly inhibitory.

Pyruvate and lactate were also shown to have a

slightly stim ulatory effect on CPT A (Table 6).

Mitochondria used in the assay for CPT A were kept intact by maintaining
the osm olarity of the assay m ixture as described.

Respiratory control ratios,

using palm itoylcarnitine as substrate, and NADH dehydrogenase activities were
taken as indicators of intactness.

Only mitochondrial preparations w ith a

respiratory control ratio greater than 4.0 and NADH dehydrogenase activity
less than 50 nm ol/m in/m g protein were used for the CPT A assays.

In addi

tion, there was very little loss (less than 2%) of CoASH derivatives under the
assay conditions (Table 7).

This indicates th a t the CoASH derivatives were

not exposed to thioesterase which is present in the mitochondrial m atrix.83

As expected, malonyl-CoA is a potent inhibitor of rat heart CPT A.
Approximately 40% inhibition is obtained w ith 1 /zM malonyl-CoA under the
conditions used (Table 8. Figure 5). Saggerson77 found 50% inhibition of rat
heart CPT A w ith 1-2 /iM malonyl-CoA.

Also consistent w ith the findings of

Saggerson77 was the fact th a t Triton X-100 could abolish the inhibitory effects
of malonyl-CoA on this enzyme (Table 6). This effect has also been demon
strated w ith the liver enzyme.57

Since the presence of malonyl-CoA in the cytosol of heart tissue is not
clearly established, its inhibitory effect on CPT A may not be physiologically
significant.

Other CoASH derivatives w ith structural sim ilarities to m alonyl-
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Co A were tested for their effect on this enzyme.

Of those CoASH derivatives

examined, only succinyl-CoA had an effect on the enzyme comparable to th a t
of malonyl-CoA (Table 6).

A t 100 /xM, malonyl-CoA inhibited CPT A

activity by 69.5%, while succinyl-CoA inhibited CPT A activity by 59.3%
(Table 9).

A t 100 /xM, acetyl-CoA did not inhibit CPT A activity, w hile

acetoacetyl-CoA and methylmalonyl-CoA inhibited the enzyme by 5.8% and
23.0%, respectively.

This agrees w ith the results of M ills et al.,134,135 who

reported that, for rat liver, heart, and skeletal muscle mitochondrial CPT A,
the inhibitory potency of CoASH derivatives followed the order malonyl-CoA
> succinyl-CoA > methylmalonyl-CoA
McGarry

et

al.,57 demonstrated

th a t

> propanoyl-CoA > acetyl-CoA.
at

10 /xM CoASH, acetyl-CoA,

propanoyl-CoA, and methylmalonyl-CoA did not inhibit rat liver CPT, while
malonyl-CoA inhibited this enzyme by 40%.

This indicates th a t it is im por

ta n t for the inhibitory compound to have a straight chain carbon skeleton w ith
a carboxyl group on the term inal carbon in order for it to exert a significant
effect on the enzyme.

Succinyl-CoA is not as potent an inhibitor of ra t heart CPT A as
malonyl-CoA.

W hile 1 /xM malonyl-CoA inhibits this enzyme by 40%,

succinyl-CoA has no effect a t this concentration (Table 8, Figure 5).

As shown

in Table 8 and Figure 5, increasing the concentration of succinyl-CoA from 1 to
100 /xM had an increasingly inhibitory effect of the enzyme.

However, inhibi

tion by suocinyl-CoA was alw ays less than the inhibition by the same concen
tration of malonyl-CoA.

Since the inhibition of ra t heart CPT A by succinyl-CoA was significant, it
w as considered th a t succinyl-CoA might be an inhibitor in vivo.

In order for
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succinyl-CoA to be a physiological inhibitor of the CPT A, it m ust be present
in the cytosol and its concentration m ust change in response to metabolic
changes.

Since, succinyl-CoA does not cross the m itochondrial membrane, any

succinyl-CoA in the cytosol m ust be produced in th a t subcellular com partm ent.
In order to determine w hether succinyl-CoA can be formed in the cytosol, heart
tissue was fractionated into cytosolic and extra-cytosolic fractions or cytosolic
and m itochondrial fractions.

Each subcellular. fraction w as assayed fo r suc

cinate thiokinase. Enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase,
and citrate synthase activities were measured as mitochondrial m atrix m arker
enzymes.

As shown in Table 10 and 11, the cytosolic fraction does exhibit

succinate thiokinase activity.

However, the percent of to tal succinate thio

kinase activity in the cytosol falls in the same range as th at for the three m ito
chondrial m atrix marker enzymes present in the cytosol.

Thus, the level of

succinate thiokinase activity in the cytosolic fraction of ra t heart is not
significantly different than the level expected due to leakage of mitochondrial
m atrix enzymes.

The leakage of mitochondrial enzymes is much higher for

heart than for other tissues because harsher treatm ent is required for subcellu
lar fractionation due to the toughness of the heart tissue.

Based on these

results it is unlikely th a t the cytosol of rat heart contains a high enough suc
cinate thiokinase activity to maintain a level of succinyl-CoA inhibitory to the
CPT A enzyme.

Since there was no effector of either the fa tty acyl-CoA synthetase or the
CPT enzymes which inhibited at a level deemed to be physiologically significant
or was dem onstrated to be in the cytosol, fu rth er kinetic studies of the
observed inhibitions were not undertaken.
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Although much evidence exists for the regulation of /3-oxidation via the
CPT enzyme or fa tty acyl-CoA synthetase enzyme in tissues other th an heart,
it appears th a t these enzymes are not points of regulation fo r /3-oxidation in
heart mitochondria.

Aas et al.,2 found that, under nutritional conditions (carbohydrate-starved
or fat-fed) which increase CPT activity levels in ra t liver, neither CPT activity
nor fa tty acyl-CoA synthetase activity is affected in heart.

They suggested

th a t regulation of fa tty acid metabolism in heart is regulated by availability of
substrates.

Oxidation of Unsaturated Fatty Acids in Mammalian Heart and Liver
Mitochondria
As shown in Table 12, the rates of oxidation of palm itoyl-CoA, oleoylCoA and linoleoyl-CoA in ra t liver mitochondria are approxim ately the same.
Christopherson and Bremer136 , found the rates of oxidation of palm itoyl
carnitine and oleoyl-carnitine in liver m itochondria to be the same, whereas
th at of linoleoyl-camitine was slightly lower and decreased w ith time. Reid
and Husbands137 found th a t the oxidation rate of oleate and linoleate was
higher than th at of palm itate in ra t liver mitochondria.

The rate of oxidation

of linoleoyl-CoA in rat heart mitochondria is slightly less th an th a t observed
using palmitoyl-CoA or oleoyl-CoA as substrate.

This agrees w ith th e results

of Christopherson and Bremer136 for oxidation of the corresponding carnitine
derivatives.

Lawson and H olm an138 showed a slightly higher rate of oxidation

of linoleoyl-CoA as compared to oleoyl-CoA in ra t heart m itochondria.

Brown

adipose tissue mitochondria also show sim ilar oxidation rates w ith p alm itoyl-
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and linoleoyl-cam itine.139

Assuming complete oxidation of the substrate in rat heart mitochondria, it
w as possible to calculate the nmoles of substrate consum ed/m in/m g protein
(Table 13).

Comparing these values to the specific activities of the three

enzymes studied in this tissue (Table 14)91 , it is evident th a t the levels of
o

2

cis-A -trans-A -enoyl-CoA isomerase and 2,4-dienoyl-CoA reductase are in
excess of th a t required for the oxidation of linoleoyl-CoA via the pathw ay pro
posed by Cuebas and Schulz.88 3-Hydroxyacyl-CoA epimerase shows a greater
specific

activity

w ith

3-D-hydroxydodecanoyl-CoA

than

w ith

3-D-

hydroxyoctanoyl-CoA as substrate.91 If the specific activity for the epimerase
in heart mitochondria using the C-12 substrate (3.42 nm ol/m in/m g protein) is
compared to the specific activity for linoleoyl-CoA oxidation (3.06 nmol
consum ed/m in/m g protein) in heart mitochondria, it w ould appear th a t this
level of enzyme is sufficient to support oxidation of linoleoyl-CoA in heart
m itochondria via the pathw ay proposed by Stoffel and Caesar.84 However,
according to this pathw ay, oxidation of linoleoyl-CoA w ould result in the for
m ation of 3-D-hydroxyoctanoyl-CoA as an intermediate and not the 3-Dhydroxydodecanoyl-CoA (Figure 2A).

The specific activity of the epimerase in

ra t heart m itochondria using 3-D-hydroxyoctanoyl-CoA as substrate (2.0
nm ol/m in/m g protein)91 is significantly low er than w h at is required to explain
the level of oxidation of linoleoyl-CoA in this tissue.

Thus, it may be con

cluded th a t at least a portion of the linoleoyl-CoA is oxidized by a pathw ay
other than the one proposed by Stoffel and Caesar84 in ra t heart mitochondria
and th a t the 3-hydroxyacyl-CoA epimerase is not necessary for the degradation
of linoleoyl-CoA.
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Although 3-hydroxyacyl-CoA epimerase has been reported to exist in
significant am ounts in liver m itochondria84’91 >140 a rigorous stu d y of the sub
cellular location of this en 2ym e in ra t liver has shown it to be associated w ith
peroxisomes, and not present in m itochondria.141 Therefore, the epimerase can
not function in mitochondrial /3-oxidation of unsaturated fa tty acids.

Inhibition of Pyruvate Dehydrogenase Complex by Derivatives of 3Mercaptopropanoic Acid
Since 3-mercaptopropanoyl-CoA was able to substitute fo r CoASH in the
thiolase reaction98 , it was thought th a t this compound might also be a sub
strate for pyruvate dehydrogenase.

W hen CoASH was excluded from the

assay m ixture and the reaction was initiated w ith 3-mercaptopropanoyl-CoA
(to 65 £iM), the reaction rate and extent observed could be to tally accounted
for by some sm all am ount of CoASH known to be present in the 3mercaptopropanoyl-CoA

solution.

Thus,

it

was

assumed

th a t

3-

mercaptopropanoyl-CoA could not substitute for CoASH in the pyruvate dehy
drogenase reaction.

However, pyruvate dehydrogenase complex can utilize a-k eto b u ty rate as
substrate to produce propanoyl-CoA which is an end-product inhibitor of this
enzyme.12 Thus, it was expected th a t 3-mercaptopropanoyl-CoA w ould inhibit
the pyruvate dehydrogenase complex.

Inhibition of pyruvate dehydrogenase by 3-mercaptopropanoyl-CoA was
dem onstrated to be 50% at 12.6 /zM, and approached a maximum of 80% inhi
bition at a concentration of 100 /zM (Figure 6A).

The degree of inhibition
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caused by 3-mercaptopropanoyl-CoA was found to be a function of time, but
was dem onstrated to be about 50% complete a t approxim ately 1 m in (Figure
6B).

The norm al product of pyruvate dehydrogenase is acetyl-CoA.

It is well

know n th a t acetyl-CoA exerts end-product inhibition on this enzyme.142 Since
it has been dem onstrated th a t 3-mercaptopropanoic acid is converted to Sacetyl-3-m ercaptopropanoyl-CoA by mitochondrial enzymes,98 it was expected
th a t the S-acetyl-3-mercaptopropanoyl-CoA thus formed w ould inhibit m ito
chondrial respiration by inhibiting the key enzyme, pyruvate dehydrogenase.

Under optim al conditions, 5.2 /iM S-acetyl-3-mercaptopropanoyl-CoA
inhibited the enzyme by 50%, w hile 100 yuM of this compound gave 90% inhi
bition

(Figure

6A).

The

degree of

inhibition

caused

by

S-acetyl-3-

mercaptopropanoyl-CoA was found to be a function of time, yet was greater
than 50% complete after only 5 seconds (Figure 6B).

The reversibility of the inhibition by S-acetyl-3-mercaptopropanoyl-CoA
was investigated by subjecting the inhibited enzyme complex to rapid gel filtra
tion on Sephadex G-50.

If th e inhibition is reversible, this process could

restore enzyme activity through removal of the inhibitor.

As can be seen in Table 15, rapid gel filtration did not result in the reac
tivation of the inhibited enzyme.

Thus, the inhibition is irreversible.

A lthough only approximately 50% of the enzyme activity was recovered during
this process, the activity in the inhibited sample relative to the control was the
same prior to and subsequent to filtration and therefore indicated no recovery
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of activity.

In the absence of BSA all enzyme activity is lost, w hile increasing

the BSA content of the applied sample and washing the column w ith BSA
increased the activity recovered.

Therefore, it is presumed th a t loss of enzyme

activity during rapid gel filtration was due to a loss of protein on the column.
Since activity was not restored to the inhibited enzyme by rapid gel filtration,
the eluate w as tested for the presence of S-acetyl-3-mercaptopropanoyl-CoA by
HPLC.

It was determined th a t only 8.4% of the applied S-acetyl-3-

mercaptopropanoyl-CoA remained in the eluate.
m ixture for this sample contained 0.8

/jlM

This m eant th a t the assay

S-acetyl-3-mercaptopropanoyl-CoA.

This concentration of inhibitor could not account for the observed inhibition.
In fact, if the inhibition were reversible, we w ould expect recovery of the
enzyme activity to alm ost 100%.

Upon examination of S-acetyl-3-mercaptopropanoyl-CoA by HPLC tech
niques, it was discovered th a t the solution contained three major contaminants:
acetyl-CoA, 3.8 ± 1.8%; dim er CoA, 0.8 ± 0.4%; and an unidentified com
ponent, 8.1 ± 1.1%.
0.1% pure.

Thus, the S-acetyl-3-mercaptopropanoyl-CoA was 88.3 ±

A ttem pts to purify the S-acetyl-3-mercaptopropanoyl-CoA by

preparative HPLC resulted in a preparation which did not exhibit the inhibi
to ry potency of the original solution, although none of the other peaks could
account for the observed inhibition.

In an effort to confirm th a t S-acetyl-3-

mercaptopropanoyl-CoA was the inhibitor, it was synthesized enzymatically
via the thiolase reaction.

The inhibitory potency of enzym atically-synthesized

S-acetyl-3-mercaptopropanoyl-CoA was compared to th a t of chemicallysynthesized
CoA.
complex

S-acetyl-3-mercaptopropanoyl-CoA

and

3-mercaptopropanoyl-

As can be seen in Table 16, inhibition of the pyruvate dehydrogenase
is

approximately

the same for enzym atically and chemically
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synthesized S-acetyl-3-mercaptopropanoyl-CoA.

A som ew hat lesser degree of

inhibition was observed here than was previously evidenced (Figure 6).

It is

likely this is due to the higher concentration of protein, especially BSA (w hich
is known to bind certain CoA derivatives) and thiolase (w hich probably also
binds 3-mercaptopropanoyl-CoA and S-acetyl-3-mercaptopropanoyl-CoA, the
substrate and product, respectively, in the thiolase reaction).

Although citrate has been dem onstrated to inhibit the pyruvate dehydro
genase reaction,12’ 143 the maximum am ount of citrate (60 / aM) which might be
produced under these reaction conditions was dem onstrated to have no effect on
the activity of pyruvate dehydrogenase.

The extent of inhibition observed w ith both 3-mercaptopropanoyl-CoA
and S-acetyl-3-mercaptopropanoyl-CoA was dependent on the preincubation
conditions (Figure 7, 8, Table 17, 18).

Maximal inhibition was observed when

the enzyme was reacted w ith the inhibitor in the presenoe of either pyruvate
and CoASH or NADH.

These tw o conditions tend to prom ote reduction of the

lipoate moiety of the enzyme.

Somewhat less inhibition was observed when

only CoASH, or CoASH and pyruvate in the absence of TPP were in the prein
cubation m ixture.

Probably under these conditions CoASH alone could pro

mote reduction of the lipoate moiety.

The least inhibition occurred under

those conditions which prom ote oxidation of the lipoate moiety of the enzyme,
i.e. when NAD+ was in the preincubation m ixture.

It is suggested th a t inhibi

tion by 3-mercaptopropanoyl-CoA and S-acetyl-3-mercaptopropanoyl-CoA
requires the lipoate moiety of the enzyme to be in the reduced state.

Under

other conditions, the presence of inhibitor caused the reaction rate to decrease
w ith time.

Addition of CoASH or pyruvate to the system after inhibition of
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the enzyme had no effect on reaction rate.

A ddition of fresh enzyme to the

system restored the reaction rate to a rate somewhat less than the control
values, indicating th a t the assay system was intact and th a t there w as no accu
m ulation of inhibitory product in the m ixture.

A t some point in th e pyruvate

dehydrogenase reaction, the reduced lipoate is made available.

This may

account for the observed increase in inhibition during the course of th e reaction.

In general, it was found th a t inhibition of pyruvate dehydrogenase com
plex, in the absence of substrates in the preincubation m ixture varied substan
tially from enzyme preparation to preparation. Since the degree of oxidation or
reduction of lipoate moieties is not altered by the preincubation conditions in
this case , it is assumed that the degree of observed inhibition reflects the degree
of reduction of the lipoate moieties of the enzyme preparation.

One notable difference between inhibition by the tw o compounds bears
mentioning.

The enzyme was, to a small degree, protected from inhibition by

S-acetyl-3-mercaptopropanoyl-CoA when pyruvate was included in the prein
cubation m ixture.

Under this condition, the lipoate would be acetylated and

might not be as accessible to modification as in the reduced state.
same conditions, however,
enhanced somewhat.

inhibition

by

Under the

3-mercaptopropanoyl-CoA

was

Apparently the acetylation of the lipoate moiety

enhances inhibition by 3-mercaptopropanoyl-CoA.

One possible explanation is

th a t the 3-mercaptopropanoyl-CoA might participate, to some sm all degree, in
the

lipoate

acetyltransferase

mercaptopropanoyl-CoA

and

(E2)
reduced

reaction

to

produce

lipoate.

3-M ercaptopropanoyl-CoA

w ould thus inhibit the enzyme via this additional mechanism.

S-acetyl-3-
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The pyruvate dehydrogenase complex contains three enzymes; pyruvate
dehydrogenase (EC 1.2.4.1), lipoate acetyl transferase (EC 2.3.1.12), and dihydrolipoyl dehydrogenase (EC 1.6.4.3).

The reactions catalyzed by the enzymes

in the complex are illustrated in Figure 9.

The reaction catalyzed by the com

plex has an absolute requirement for pyruvate, CoASH, and NAD+. Thus, the
overall reaction can be initiated by the addition of one or more of any of these
substrates.

The order of addition of these substrates m ay have an effect on the

state of the enzyme, particularly on the lipoate portion of the lipoate acetyl
transferase.

In addition, it can be seen th a t the process of the reactions brings

the lipoate moiety through three states; the acetyl-bound state, the oxidize4
state, and the reduced state.

Inhibition of the component enzymes of the pyruvate dehydrogenase com
plex by S-acetyl-3-mercaptopropanoyl-CoA was also maximal under preincu
bation conditions, which tend to promote reduction of the lipoate moiety.

Assessing the effect of S-acetyl-3-mercaptopropanoyl-CoA on pyruvate
dehydrogenase, the first component enzyme of the complex, proved impossible.
Due to the slow rate of the reaction, it was not possible to assay the enzyme by
the m ethod involving reduction of DCPIP.

This method has been shown to

cause the progressive inhibition of the pig heart pyruvate dehydrogenase com
ponent by modification of enzyme-bound TPP.144 The method employed was
based on the reduction of ferricyanide and yielded a specific activity of 0.21
/xm ol/hr/m g protein.

This value is comparable to th a t of 5.7 /um ol/hr/m g

protein reported by Hayakawa et a l . , 124 who used slightly different conditions,
which may have enhanced the activity of the enzyme.

In any case, the enzyme

activity was too low for inhibition to be effectively examined.
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The second component enzyme of the complex, lipoate acetyl transferase,
is usually assayed by the determination of heat-stable thioester form ed in the
reaction of constantly generated acetyl-CoA w ith dihydrolipoam ide in the
absence of CoASH.

This assay could not be employed because th e inhibitor

molecule, S-acetyl-3-mercaptopropanoyl-CoA, is a heat-stable thioester.

In

addition, the inhibitor molecule is thought to act by form ing a heat-stable
thioester w ith dihydrolipoate or dihydrolipoamide.

The first and second component enzymes of the pyruvate dehydrogenase
complex were assayed together by measuring, via the citrate synthase reaction,
the am ount of acetyl-CoA produced.

As shown in Table 19, when lipoamide

was absent from the preincubation m ixture, but pyruvate was present, the
inhibition was significantly greater than under other conditions.

This condi

tion tended to promote the reduction of the endogenous lipoamide during the
preincubation period, thus making it available for reaction w ith the inhibitor.
It should be noted th at exogenous lipoamide cannot participate in these reac
tions directly.113 It can, however, drive the reaction by oxidizing enzymebound dihydrolipoate in the absence of NAD+ by the following reaction
sequence:

I

S

S

HS

SH

HS

S S

SH

HS

SH

S

S

Thus, endogenous lipoate w ill be regenerated for reaction w ith pyruvate.

The

fact th a t inhibition was nearly the same in the presence or absence of lipoam
ide, when pyruvate was om itted during preincubation, suggests th a t m ost of
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the endogenous, enzyme-bound lipoate was in the oxidized state.

Including

pyruvate in the preincubation, but om itting lipoamide, would tend to generate
endogenous enzyme-bound dihydrolipoate in the process of the reaction.

Inhi

bition was enhanced under these conditions, suggesting th at reduced endogenous
lipoate is necessary for the inhibitor to exert its effect.

The third component enzyme of the pyruvate dehydrogenase complex,
dihydrolipoyl dehydrogenase, was assayed in both the forw ard and reverse
direction by measuring the appearance or disappearance of NADH.

Exogenous

dihydrolipoam ide or lipoamide can be, and was, used as substrate for the for
w ard or reverse reaction, respectively.

Because, under conditions where the

inhibition of the pyruvate dehydrogenase complex was minimal, inhibition
increased w ith time (Figure 8), it was thought th a t some process of the reaction
(possibly making reduced lipoate available) contributed to the inhibition.

By

assaying the dehydrogenase enzyme w ith exogenous lipoamide, the step thought
to be critical to inhibition (enzym atically catalyzed binding of S-acetyl-3mercaptopropanoyl-CoA to reduced endogenous lipoate) was bypassed.

Thus,

it was expected th a t S-acetyl-3-mercaptopropanoyl-CoA w ould have no effect
on this enzyme.

C ontrary to expectation, Table 20 shows th a t dihydrolipoyl dehydro
genase was inhibited in both directions under certain conditions.

In the fo r

w ard direction, the enzyme w as inhibited only when dihydrolipoamide was in
the preincubation m ixture together w ith the inhibitor and when NAD+ was
used to initiate the reaction.

In the reverse direction, inhibition only occurred

w hen NADH was included in the preincubation m ixture w ith the inhibitor and
lipoamide was used to initiate the reaction.

These data are not inconsistent
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w ith the hypothesis th a t S-acetyl-3-mercaptopropanoyl-CoA reacts irreversibly
w ith endogenous dihydrolipoate.

However, the fact th a t inhibition of the

dehydrogenase portion of th e enzyme still occurs in the presence of exogenous
lipoamide indicates th a t the inactivation of endogenous lipoate cannot totally
explain the observed inhibition of the pyruvate dehydrogenase complex.

One

possible explanation is apparent from the fact th a t inhibition of the dehydro
genase was only seen under those conditions which tended to promote reduction
of endogenous lipoate.

In fact, under conditions which promoted oxidation of

endogenous lipoate, no significant inhibition was observed.
could

be expanded to include the possibility

The hypothesis

th a t covalently modified

endogenous lipoate m ay compete for the lipoamide site on the dehydrogenase.
This modified endogenous dihyd ro 1ipoate w ould be a very effective competitive
inhibitor compared to covalently modified exogenous lipoamide, because of its
close proxim ity to the active site of the enzyme.

However, it cannot be ruled out th a t the S-acetyl-3-m ercaptopropanoylCoA directly inhibits the dihydrolipoyl dehydrogenase reaction.

Several inhi

bitors of this enzyme are know n.145’ 146 In the E. coli pyruvate dehydrogenase
complex, p-[(brom oacetyl)-am ino]phenyl arsenoxide binds first to the reduoed
lipoyl residues (via its arsenoxide m oiety) on the lipoate acetyltransferase.
This is followed by an irreversible alkylation of histidine and cysteine in the
active site of the dihydrolipoyl dehydrogenase, resulting in inhibition of this
reaction and the overall reaction of the pyruvate dehydrogenase complex.145 Pig
heart dihydrolipoyl dehydrogenase is inhibited by l,3-bzs~(2-chloroethyl)-lnitrosourea.146 This inhibition is dependent on the reduction of a cystine
disulfide located w ithin the active site of the enzyme. The inhibition can be
prevented by preincubation of the enzyme w ith lipoamide.

Thus, inhibition of
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dihydrolipoyl dehydrogenase by S-acetyl-3-m ercaptopropanoyl-CoA m ay fol
low a sim ilar pattern in th a t this component enzyme is inhibited tinder reduc
ing conditions, and the inhibition is prevented by preincubation of the enzyme
w ith lipoamide. This, however, w ould have to be in addition to the inhibition
of the E1E2 portion of the pyruvate dehydrogenase complex which was demon
strated (Table 19).

The site of inhibition by S-acetyl-3-mercaptopropanoyl-CoA was fu rth er
investigated by examining its effect on the incorporation of radioactively
labelled acetyl groups from acetyl-CoA into the pyruvate dehydrogenase com
plex.

In the presence of NADH, the lipoate moiety of the lipoate acetyl-

transferase (E2) is reduoed via the lipoamide dehydrogenase (E3) reaction. In
the reverse reaction, the reduced lipoate can be acetylated from the product,
acetyl-CoA.

Since mammalian pyruvate dehydrogenase complex contains a

dihydrolipoyl transacetylase core consisting of 60 polypeptide chains each con
taining one molecule of covalently bound lipoic acid,147 the upper lim it for ace
ty l groups bound per pyruvate dehydrogenase complex is 60.

If the acetyl-

CoA binding site is blocked by the inhibitor or the inhibitor itself reacts w ith
the reduced lipoate, the acetylation of the pyruvate dehydrogenase complex
w ill be inhibited.

It m ust be pointed out th a t there is another binding site for

acetyl-CoA, demonstrated for the E. coli enzyme148' 149>150> 151 which is on the
pyruvate dehydrogenase (E l) and is a site for allosteric inhibition of th e E l
reaction.150’ 151’ 152 However, binding of acetyl-CoA to this site occurs in the
presence or absence of NADH and can therefore be accounted fo r by measuring
acetyl-CoA incorporation in the absence of NADH.

As can be seen in Table 21,

S-acetyl-3-mercaptopropanoyl-CoA does inhibit incorporation of the acetyl
group from the acetyl-CoA into the enzyme, and the degree of inhibition

-

60-

increases w ith increasing inhibitor concentration.

T hat the inhibition requires

a greater concentration of inhibitor than in the pyruvate dehydrogenase com
plex assay can be explained by the greater concentration of enzyme protein
used.

These results lend support to the hypothesis th a t the enzyme is reacting

w ith the inhibitor.

In fact, in an experiment where BSA w as included in the

reaction in an am ount ten times th at of pyruvate dehydrogenase complex, inhi
bition was significantly reduced, but still occurred and increased w ith increas
ing S-acetyl-3-mercaptopropanoyl-CoA concentration.

The data strongly suggest th a t S-acetyl-3-mercaptopropanoyl-CoA inhi
bits the pyruvate dehydrogenase complex by

donating

the S-acetyl-3-

mercaptopropanoyl group to the dihydrolipoate moiety of th e enzyme to form
S-acetyl-3-mercaptopropanoyl lipoate, thereby making the lipoate unavailable
to accept an acetyl group in the normal reaction.

This w ould be sim ilar to the

irreversible inhibition of the E. coli pyruvate dehydrogenase complex by 2bromopyruvate.

This inhibition is due to the reductive bromoacetylation of

lipoyl moieties of the E2 subunit.153’ 154 It is suggested, in addition, th a t Sacetyl-3-mercaptopropanoyl-CoA is formed intram itochondrially under certain
conditions and, once formed, inhibits pyruvate-supported respiration by direct
inhibition of the pyruvate dehydrogenase complex.

Some prelim inary w ork has been done to examine the possibility th a t Sacetyl-3-mercaptopropanoyl-CoA
pyruvate-supported respiration.

formed

intram itochondrially

affects

Since 3-mercaptopropanoic acid is know n to

be activated in rat heart mitochondria98 and to inhibit palm itoy W -carnitinesupported respiration97 , its effect was compared to th a t of S-acetyl-3mercaptopropanoic

acid.

As

can

be

seen

in

Table

22,

S-acetyl-3-
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mercaptopropanoic acid was comparable to 3-mercaptopropanoic acid in its
ability to inhibit both palmitoyl-Z-carnitine- and pyruvate-supported respira
tion in both ra t heart and ra t liver mitochondria.

One unusual aspect of these

data is th a t pyruvate-supported respiration was inhibited significantly in rat
liver mitochondria, but not in ra t heart mitochondria.

This is consistent w ith

the observation th a t propanoate (know n to be activated to propanoyl-CoA
which inhibits pyruvate dehydrogenase) inhibits flux through the pyruvate
dehydrogenase in perfused rat liver, but not ra t heart.155 This may have to do
w ith the difference in the activation enzymes of these tissues and th u s the
difference in intram itochondrial concentration of the CoA derivative maintained
in each of these tissues.

The data in this table indicate that S-acetyl-3-mercaptopropanoyl-CoA is
formed intram itochondrially and is as potent an inhibitor as the m etabolites of
3-mercaptopropanoic acid.

The fact th a t S-acetyl-3-mercaptopropanoic acid

was also a potent inhibitor of palmitoyl-Z-carnitine-supported respiration and
th a t the pattern of inhibition so closely paralleled th a t of 3-mercaptopropanoic
acid led to the suspicion th a t perhaps the acetyl group is cleaved from the Sacetyl-3-mercaptopropanoic acid to form 3-mercaptopropanoic acid an d /o r its
derivatives.

If this were the case, the data w ould be the same because inhibi

tion w ould be due to 3-mercaptopropanoic acid metabolites.

To avoid this

confusion, w ork was pursued in a manner th at was considered to result in the
form ation of S-acetyl-3-mercaptopropanoic acid intram itochondrially w ithout
the introduction of S-acetyl-3-mercaptopropanoic acid.

One w ay in which this

could be accomplished in rat heart mitochondria was to supply acetoacetate as
substrate so th a t acetoacetyl-CoA would be formed intram itochondrially.
the

presence of 3-mercaptopropanoyl-CoA,

thiolase

w ould

In

utilize both
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substrates to form , as product, S-acetyl-3-mercaptopropanoyl-CoA.98

The data from using this strategy are presented in Table 23.

As can be

seen in this table, pyruvate-supported respiration in ra t heart mitochondria is
not inhibited by 3-mercaptopropanoic acid w hen m alate is used as primer.
Pyruvate-supported respiration is inhibited, however, w hen acetoacetate (20
jj .

M)

is

being

metabolized.

mercaptopropanoyl-CoA

is

This
formed

pyruvate-supported respiration.

w ould

indicate

th a t

intram itochondrially

S-acetyl-3-

and

inhibits

However, pyruvate-supported respiration is

inhibited to the same extent in the absence of acetoacetate, when a ketoglutarate is used as primer.

This may mean th a t a-ketoglutarate somehow

provides the acetyl group involved in the acetylation of 3-mercaptopropanoylCoA.

As stated previously, both 3-mercaptopropanoyl-CoA and S-acetyl-3mercaptopropanoyl-CoA inhibit the pyruvate dehydrogenase complex.
optim al

conditions,

50%

inhibition

was

obtained

at

12.6

Under
£iM

3-

mercaptopropanoyl-CoA or 5.2 *uM S-Acetyl-3-mercaptopropanoyl-CoA.

In

addition, inhibition by S-acetyl-3-mercaptopropanoyl-CoA was greater than
50% complete in 5 seconds.

W hile th a t caused by 3-mercaptopropanoyl-CoA

was 50% complete in approxim ately 1 min.

Both inhibitors appear to be more

potent under conditions where the endogenous lipoate moiety of the enzyme is
reduced.
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Table 1. Effects o f M etab olites and C oenzym es on th e F atty A cyl-C oA
S y n th eta se o f Rat H eart M itochon d ria

1
5
10
10
1
1
10
0.1
5

Effectors
(nm ol/m in/m g protein)
None
mM octanoylcam itine
mM acetoacetate
mM D L-3-hy droxy b u ty rate
None
mM pyruvate
mM NAD+
mM NADH
None
mM Lactate
mM fructose-1,6-diphosphate
mM ADP

Specific A ctivity
(%)
11 ± 1
11 ± 3
10 ± 1
10 ± 1
10 ± 4
11 ± 1
11 ± 1
11 ± 2
7 ±2
7.8 ± 0.1
7 ± 1
4.0 ± 0.2

Relative A ctivity
100
104
96
93
100
115
109
116
100
114.5
107
58.7

Values are means ±S.E. The values are based on three assays w ith one
preparation of mitochondria. Each grouping used a different mitochondrial
preparation. The concentration of each effector was selected such th a t it was
likely to be equal to or greater than its concentration in ra t heart cytosol. This
was estim ated from the literature values of the acylcarnitine8, acetoacetate ,
/3-hydroxy buty rate , pyruvate , NAD+C, NADH , lactate , fructose-1,6diphosphate , and ADP content of heart tissue in /im ole/g fresh w t. and the
value of 2 m l/g dry tissue6 fo r the cytosolic space in heart muscle. Additional
details of the experiment are described under "Experimental Procedures".

a M. M. Abdel-Kader, and G. W olf in Recent Research on Carnitine, ed. G. W olf, p. 147, M.l.T.
Press, Cambridge, Mass., 1965.
^ O. Kraupp, L. Adler-Kastner, H. Niessner, and B. Plank, Eur. J. Biochem., vol. 2, p. 197, 1967.
c H. B. Burch, O. H. Low ry, and P. von Dippe, J. Biol. Chem., vol. 238, p. 2838, 1963.
** P. Arese, A. Bosia, and G. Pescarmona, unpublished results, in Methods in Enzym atic Analysis,
ed. H. U. Bergmeyer, and K. Gawehn, vol. 4 , p. 2295, Academic Press, Inc., N.Y., 1974.
e H. E. Morgan, D. M. Regen, and C. R. Park, J. Biol. Chem., vol. 23 9 , pp. 3 6 9 -3 7 4 , 1964.
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Table 2. Effect o f P a lm ito y lc a rn itin e on R at H e art M ito ch o n d ria F a tty
Acyl-CoA S y n th etase

Concentration
(mM )
0
0.020
0.20
1.00
0
0.2
0.5
2.0

Specific A ctivity
(nm ol/m in/m g protein)
13 ± 1
11 ± 3
10 ± 1
7 ± 1
12 ± 1
10 ± 1
9 ±2
7 ± 1

% Inhibition
0
17
25
45
0
17
24
37

Values are means ±S.E. The values are based on three assays w ith one
preparation of mitochondria. Each grouping of data used a different mitochon
d rial preparation. Additional details of the experiment are described under
" Experim ental Procedures".
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Table 3. S e p a ra tio n o f O uter M ito c h o n d ria l M em brane a n d In te rm e m 
b ra n e F rac tio n From In n e r M em b ran e F rac tio n o f Beef H eart
M ito c h o n d ria b y D ig ito n in T re a tm e n t

F a tty Acyl-CoA Synthetase
Specific A ctivity of Mitochondria
A ctivity of "outer" fraction
Total A ctivity of mitochondria used
Total A ctivity Recovered in "outer" fraction
C arnitine Palm itoyltransferase
Specific A ctivity of Mitochondria
Specific A ctivity of "outei" fraction
Total A ctivity in "outer" fraction

8.2
28.4
791
44

nm ol/m in/m g protein
nm ol/m in/m l
nm ol/m in
nm ol/m in

4.4
2.1
20.2

nm ol/m in/m g protein
nm ol/m in/m g protein
nm ol/m in

C arnitine palm itoyltransferase activity was assayed by the spectrophotometric
method. Details of the experiment are described under "Experimental Pro
cedures" .
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Table 4. E ffect o f R egulators o f P ro te in K inases o r Phosphatases on th e
A c tiv ity o f F a tty A cyl-CoA S y n th e ta s e
Experim ents were perform ed using heart tissue homogenate. Specific
activity is expressed in nm ol/m in/m g protein. Values are means ±
S. E. Figures in parentheses are th e num ber of observation w ith
sam ples from different animals.
Each sample w as assayed a
m inim um of tw o times. O ther details of the experiment are
described under "Experimental Procedures".
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Effectors Included in
Preincubation M ixture
O nly
Specific
%
A ctivity
Stim ulation
Preincubation at 25°C for 20 m in in:
15.4 ± 0 .5 (4 )
0
100 mM Tris-HCl buffer,
pH 7.4

Effectors Included in
Preincubation M ixture
and A ssay Mixture
Specific
%
A ctivity
Stim ulation
15.4 ± 0 .5 (4 )

0

Buffer, 5 mM Mg-ATP,
0.25 mM CaCl2

16.8 ± 1.1(3)

9.1

17.5 ± 1.1(3)

13.7

Buffer, 5 mM Mg-ATP,
calm odulin (1 /ig/m g protein)

18.5 ± 1.1(3)

20.5

18.9 ± 1.0(3)

23.1

Buffer, 5 mM Mg-ATP,
0.25 mM CaCl2,
calm odulin (1 MS/mg protein)
Buffer

19.0 ± 0 .5 (3 )

23.5

17.6 ± 0 .7 (3 )

14.4

12.6 ± 0 .4 (5 )

0

12.8 ± 0 .4 (5 )

0

Buffer, 5 mM Mg-ATP,
25 fxM CaCl2

12.5 ± 2 .0 (4 )

0

12.3 ± 1.1(4)

0

Buffer, 5 mM Mg-ATP,
1 mM EGTA

13.1 ± 0 .5 (3 )

2.9

13.2 ± 0 .6 (3 )

3.7

Buffer, 5 mM Mg-ATP,
13.8 ± 0 .4 (5 )
25 /uM C aC l.,
1 mM EGTA
Preincubation at 25°C for 30 m in in:
Buffer
13.1 ± 1 .0 (4 )

8.5

13.0 ± 1.6(5)

2.0

0

13.2 ± 1.0(4)

0

Buffer, 0.1 mM cAMP,
5 mM M gCl2

13.4 ± 1.0(4)

2.8

12.7 ± 0 .6 (4 )

0

Buffer, 0.1 mM cAMP,
5 mM Mg-ATP

13.6 ± 1.9(4)

4.0

14.7 ± 1.0(4)

12.3

Buffer, 0.1 mM cAMP, 5 mM
14.0 ± 0 .2 (3 )
Mg-ATP added after 15 min
Preincubation at 25°C for 20 min in:
Buffer
13.0 ± 1.8(5)

7.5

13.8 ± 0 .2(3)

5.7

0

13.0 ± 1.8(5)

0

Buffer, 5 mM ATP/M gCl2

12.2 ± 1.4(5)

6.1

12.2 ± 1.4(5)

6.1

Buffer, 5 mM ATP/M gCl ,
50 mM KF

12.1 ± 1.1(5)

7.1

12.1 ± 1.0(3)

6.8

Buffer, 5 0 mM KF

12.7 ± 0 .6 (5 )

2.7

12.7 ± 0 .3(3)

2.7
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Table 5. Effecs o f M eta b o lites and C oenzym es on C a rn itin e P a lm ito y l
tra n sfera se fr o m R at H eart M itochon d ria

C arnitine palm itoyltransferase activity was assayed by the radiochemical
method. Values are means ±S.E. Figures in parentheses are the num ber of
observations w ith samples from different animals. Each sample w as assayed a
m inim um of tw o times. The concentration of each effector was selected such
th a t it was likely to be equal to or greater than its concentration in ra t heart
cytosol.
This w as estim ated from the literature values of the /3hydroxy b uty rate0, ATP°, ADP , acetylcarnitinec, fructose-1,6-diphosphate°,
NAD+ , NADH , pyruvate0, lactate0, and acylcam itine6 content of heart tissue
in Atmole/g fresh w t. and the value of 2 m l/g d ry tissue fo r the cytosolic space
in heart muscle. O ther details of the experiment are described under "Experi
m ental Procedures".

0 O. Kraup, L. Adler-Kastner, H. N iessner, and B. Plank, Ear. J. Biochem., vol. 2, p. 197, 1967.
P. A iese, A. Bosia, and G. Pescarmona, unpublished results, in M ethods o f Enzym atic Analysis,
ed. H. U. Bergmeyer, and K. Gawehn, vol. 4, p. 2295, Academic Press, Inc., N. Y., 1974.
c D. J. Pearson, and P. K. Tubbs, Biochem. J., vol. 105, p. 953, 1967.
d H. B. Burch, O. H. Low ry, and P. von Dippe, J. Biol. Chem., vol. 2 38, p. 2838, 1963.
e M. M. Abdel-Kader, and G. W olf, in Recent Research on Carnitine, ed. G. W olf, p. 147, M.I.T.
Press, Cambridge, Mass,, 1965.
^ H. E. Morgan, D. M. Regen, and C. R. Park, J. Biol. Chem., v o l. 23 9 , pp. 3 6 9 -3 7 4 , 1964.
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Table 5. E ffects o f M eta b o lites and C oenzym es on C a rn itin e P a lm ito y l
tra n sfera se fr o m Rat H eart M itochon d ria

Effectors
None
10
mM
None
5
mM
5
mM
None
1 mM
0.1 mM
1 mM
1 mM
None
10
mM
10 mM
1 mM
10
mM

/3-hydroxy b u ty rate
ATP
ADP
acety 1-Z-carnitine
fructose-1,6-diphosphate
NAD+
NADH
pyruvate
lactate
octanoy W -carnitine
/3-hydroxybutyrate

Specific A ctivity
(nm ol/m in/m g protein)
14 (1)
13 (1)
12 ± 1 (2 )
10 ± 0 (2 )
8 ± 1(2)
11 ± 0 (3 )
11 ± 3 (2 )
10 ± 1 (3 )
12 ± 2 (3 )
12 ± 1 (3 )
16 ± 5 (4 )
18 ± 1(4)
17 ± 4 (4 )
15 ± 2 (3 )
15 ± 1(4)

% Inhibition
12
18 ± 1
32 ± 5
6 ±28
15 ±10

6 ±12
8 ±8
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Table 6. Effects o f M etab olites on C arn itin e P a lm ito y ltra n sfera se A o f
Rat H eart M itochon d ria

Effectors
None
100 yuM malonyl-CoA
100 f iM methylmalonyl-CoA
100 £im acetyl-CoA
None
100 /xM malonyl-CoA
100 /xM methylmalonyl-CoA
100 ^iM acetyl-CoA
100 xxM acetoacetyl-CoA
None
100 /uM malonyl-CoA
100 mM succinyl-CoA
None
100 jjlM succinyl-CoA
100 fjLM acetoacetyl-CoA
100 /uM acetyl-CoA
100 ftM methylmalonyl-CoA
10 mM pyruvate
10 mM lactate
None
100 ytxM malonyl-CoA
100 piM malonyl-CoA + Triton X-100
0.09% Triton X-100
None
100 juM malonyl-CoA
100 /xM succinyl-CoA
100 fjiM acetoacetyl-CoA
100 /xM acetyl-CoA
100 juM methylmalonyl-CoA

Specific Activity
(nmol/min/mg protein)
12.5 (1)
5.1 (1)
10.1 (1)
13.6 (1)
7.7 (1)
3.1 (1)
7.0 (1)
9.7 (1)
8.4 (1)
9.0 (1)
3.6 (1)
4.0 (1)
13.4 (1)
7.0 (1)
13.7 (1)
13.4 (1)
11.2 (1)
16.9 (1)
17.2 (1)
16.1 (1)
2.1 (1)
13.4 (1)
12.6 (1)
11.4 ±1.0(3)
0.7 ±0.0(3)
3.5 ±0.8(3)
8.0 ±1.1(3)
9.3 ±1.1(3)
6.0 ±0.8(3)

% Inhibition
59.4
18.6
59.8
9.6

59.7
55.4
52.2
16.6

86.9
16.3
21.4
93.6
69.0
29.8
18.3
47.0

CPT A activity was assayed using the radiochemical method. Values are
means ± S. E. Figures in parentheses are the num ber of observations w ith
samples from different animals. Each sample was assayed a minimum of tw o
times. O ther details of the experiment are described in "Experimental Pro
cedures" .
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Table 7. Loss o f CoASH D e riv a tiv es D uring T im e an d C o n d itio n s o f th e
A ssay f o r C a rn itin e P a lm ito y ltra n sfe ra s e A A c tiv ity

Derivative
(100 wM)
succinyl-CoA
m alonyl-CoA
acetyl-CoA
acetoacetyl-CoA
m ethylm alonyl-CoA

Specific A ctivity
nm ol/m in/0.05 me protein
w ith o u t carnitine w ith carnitine
1.25
0.44
0
0.19
0.15
0
0
0.15
0
0

Values are based on tw o assays w ith one preparation of mitochondria. Other
details of the experiment are described under "Experimental Procedures".
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Table 8. R e latio n sh ip B etw een C o n ce n tra tio n o f M alonyl-C oA o r
Succinyl-C oA a n d Degree o f In h ib itio n o f C a rn itin e P a lm ito y l
tra n s fe ra s e A

Inhibitor
None
M alonyl-CoA

Sucdnyl-CoA

Concentration
UM)
100
10
1
0.1
0.01
100
10
1
0.1
0.01

Specific A ctivity
(nm ol/m in/m g protein)
10.4 ± 2.2
3.3 ± 0.1
4.6 ± 0 .9
6.1 ± 0.1
7.8 ± 2 .8
10.8 ± 2 .8
4.7 ± 1.2
7.6 ± 0.1
10.8 ± 0 .0
11.1 ± 0 .7
10.4 ± 1.5

% of Control
Activity
100
31
44
59
76
103
45
72
104
107
99

C arnitine palm itoyltransferase A activity w as assayed by the radiochemical
m ethod. Values are means ± S. E. Values are based on assays w ith tw o
different preparations of mitochondria. O ther details of the experiment are
described under "Experim ental Procedures".
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Table 9. In h ib itio n o f R at H eart M ito ch o n d rial C a rn itin e P a lm ito y l
tra n s fe ra s e A b y M alonyl-C oA an d S tru c tu ra lly R elated Com
pounds

Inhibitor
(100 /iM )
malonyl-CoA
succinyl-CoA
acetyl-CoA
acetoacetyl-CoA
m ethylm alonyl-CoA

Inhibition
(%)
70 ± 1 5
59 ± 0
-4 ± 2 0
6 ±27
23 ± 1 6

C arnitine palm itoyltransferase A activity was assayed by the radiochemical
m ethod. Values are based on the experimental results presented in Table 6.
O ther details of the experiment are described under " Experimental Procedures".
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Table 10. E nzym e A c tiv itie s o f S u b cellu lar F ractio n s O btained b y
M ethod I

Time
(m in)
Succinate Thiokinase
'whole heart homogenate

cytoplasm

extracytoplasm ic fraction

Enoyl-CoA Hydratase
cytoplasm
extracytoplasm ic fraction
3-H ydroxyacyl-C oA Dehydrogenase
cytoplasm
extracytoplasm ic fraction
Citrate Synthase
cytoplasm
extraclytoplasm ic fraction

Specific
A ctivity
(M m ol/m in/m g)

0
5
20
40

0
6.8
3.4
1.3

0
5
20
40

0
2.0
0.9
0.7

0
5
20

Total
A ctivity
(#tm ol/m in)

46.1

% of
Combined
A ctivity
100

12.8

27.8

0
27.3
8.5

39.0

84.4

1.0 ± 0 .2
41
±9

6.5
59

9.8
90

0.2 ± 0 .0
2
±1

1.0
2

29.9
70

0.3 ± 0 .0
6.1 ± 1 .1

1.9
8.6

18.3
81.7

Values are mean ± S. E. The values for succinate thiokinase are based on one
assay. The values for the other enzymes are based on three assays. All assays
were perform ed on the same preparation of subcellular fractions. Other details
of the experiment are included in " Experimental Procedures".
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Table 11. E nzym e A c tiv itie s o f S u b cellu lar F ractio n s O btained b y
M ethod II

Total A ctivity
(/um ol/m in)

% o f Combined
A ctiv ity

2.7 x 10'3
76.4 x 10'3

50.8 x 10'3
71.7 x 10'3

41.5
58.5

1.0 ± 0 .1
41
± 4

19.6
39

33.3
67

0.2 ± 0 .0
4 .0 ± 0 .2

3.0
3.8

44.5
55.5

0 .3 ± 0 .0
8.8 ± 0 .6

5.7
8.2

40.9
59.1

Specific A ctivity
(Atntol/m in/m g)
Succinate Thiokinase
cytosol
m itochondria
Enoyl-C oA Hydratase
cytosol
mitochondria
3-H ydroxyacyl-C oA Dehydrogenase
cytosol
mitochondria
Citrate Synthase
cytosol
mitochondria

Values are mean ± S. E. The values fo r succinate thiokinase are based on tw o
assays. The values for the other enzymes are based on three assays. A ll
assays were performed on the same preparation of subcellular fractions. O ther
details of the experiment are described under "Experimental Procedures".
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Table 12. R ates o f R esp iratio n Supported b y F a tty Acid O x id atio n in R at
L iv e r an d R at H e a rt M ito ch o n d ria
(Data is expressed in nanoatoms 0 2 consum ed/m in/m g protein)

Substrate
Palmitoyl-CoA
Oleoyl-CoA
Lineoyl-CoA
RCR

Rat Heart
167.1 ± 1 8 .8
174.0 ± 26 .1
154.1 ± 2 3 .9
4.3 ± 0.6

Rat Liver
73.7 ± 9 .7
78.7 ± 8 .9
73.9 ± 8.4
4.9 ± 0 .9

Values are means ± S. E. The values are based on three assays each w ith three
different preparations of mitochondria. Other details of the experiment can be
found under "Experimental Procedures".
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Table 13. S ubstrate U tiliz a tio n b y R at H e art M ito c h o n d ria

Substrate
Palmitoyl-CoA
Oleoyl-CoA
Linoleoyl-CoA

Specific A ctivity
(nmol consum ed/m in/m g protein)
3.6 ± 0 .4
3.4 ± 0 .5
3.1 ± 0 .5

Values are means ± S. E. The values are based on three assays each w ith three
different preparations of mitochondria. Other details of th e experiment can be
found u n d e r" Experimental Procedures".
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Table 14. A c tiv itie s o f A u x ilia r y E nzym es o f /3-O xidation R equired fo r
th e D egradation o f P olyu n satu rated F a tty A cids in R at L iv er
and Rat H eart M itoch on d ria

Enzyme
3-Hydroxyacyl-CoA epimerase
C-12 substrate
C-8 substrate
cis-A^-trans-A^-enoyl-CoA isomerase
2,4-Dienoyl-CoA reductase

Rat Heart

Rat Liver

3.4 ± 0.5(3)
2.0 ± 0.3(3)
745 ± 9 3 (3)
27.4 ± 5.1(3)

84.9 ± 8.4(7)
79.3 ± 14.4(5)
721 ± 1 3 4 (3)
73.6 ± 17.0(5)

Data is expressed in nm ol/m in/m g protein. Values are means ± S. E. Figures
in parentheses are th e num ber of observations w ith samples from different
animals. Each sam ple was assayed a m inim um of three times.
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Table 15. R ecovery o f P y ru v a te D ehydrogenase Com plex b y R apid Gel
F iltra tio n

Control
Inhibited

% volume
recovered
85 ± 4
88 ± 8

% activity
recovered
46 ± 7
49 ± 16

% of control activity
prefiltration
100
11.2 ± 2

post-filtration
100
12 ± 3

% S-acetyl-3-mercaptopropanoyl-CoA remaining in eluate - 8.4 %
Concentration of S-acetyl-3-mercaptopropanoyl-CoA in eluate = 19.8 fiM
Concentration of S-acetyl-3-mercaptopropanoylCoA in assay = 0.8 /aM

Details of the experiment can be found under "Experimental Procedures".
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Table 16. In h ib itio n o f P y ru v a te D ehydrogenase C om plex b y E n zy m ati
c a lly S yn th esized S-A cetyl-3-M ercaptopropanoyl-C oA as Com
p a re d
to
C h em ica lly
S y n th esized
S-A cetyl-3-M ercaptopropanoyl-C oA an d 3-M ercaptopropanoyl-C oA

Concentration
o f Inhibitor
(« M )
26.7
13.6
6.8

Pyruvate Dehydrogenase Complex A ctivity (% of control)
S-Acetyl-3-M ercaptopropanoyl-C oA
3-M ercaptopropanoyl-CoA
C hem ically
E nzym atically
Synthesized
Synthesized
47 ± 5
35 ± 2
35 ± 1
49 ± 10

56 ± 7

62 ±

68 ±

87

86 ± 18

1

5

The S-Acetyl-3-M ercaptopropanoyl-CoA w as enzym atically synthesized via
the thiolase reaction as described under " Experimental Procedures". The con
tro l reaction included CoASH instead of 3-mercaptopropanoyl-CoA in the
thiolase reaction. Chemically synthesized 3-m ercaptopropanoy 1-CoA and Sacetyl-3-m ercaptopropanoyl-CoA were added to the assay m ixture ju st prior to
the preincubation period. The enzyme was preincubated for 3 m in a t 30°C in
the presence of KPi, MgCL, TPP, CoASH, and pyruvate. The reaction was ini
tiated by the addition of NAD+. O ther details of the experiment are described
under "Experim ental Procedures".
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Table 17. Inhibition of Pyruvate Dehydrogenase Complex by 3Mercaptopropanoyl-CoA as a Function of Different Preincuba
tion Conditions

% of
Control

Preincubation
Components

Initiation
Components

TPP, CoASH, pyruvate

NAD4

Initial V elocity
(pm ol/m ir i/m g protein)
Inhibited
Control
1.5 ± 0.3
0.3 ± 0.1

TPP, CoASH

NAD4, pyruvate

2.7 ± 0 .3

0.6 ± 0.1

21.1

TPP, NADH

N A D 4, pyruvate, CoASH

1.6 ± 0.2

0.2 ± 0.1

5.8

TPP, pyruvate, N AD+

CoASH

2 .0 ± 0.2

1.1 ± 0 .2

54.4

TPP, CoASH, NAD+

pyruvate

2.1 ± 0 .2

1.2 ± 0 .6

72.5

TPP

NAD4, pyruvate, CoASH

1.9 ± 0 .3

0.5 ± 0.2

28.3

TPP, pyruvate

N AD4, CoASH

1.8 ± 0 .5

0.3 ± 0.1

17.1

TPP, N A D +

pyruvate, CoASH

2.2 ± 0 .1

1.7 ± 0 .1

79.1

CoASH, pyruvate

TPP, N A D 4

2.2 ± 0.5

0.4 ± 0 .1

19.5

6.5

The enzyme was preincubated fo r 3 min a t 30°C in the presence of KPi, MgCl2>
and various components of th e assay m ixture. The reaction was initiated by
the addition of those assay components not present during the preincubation.
The 3-mercaptopropanoyl-CoA, w hen included in the preincubation mixture,
w as a t a concentration of 30.5 ytiM. O ther details of the experiment can be
found under "Experimental Procedures".
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Table 18. Inhibition of Pyruvate Dehydrogenase Complex by S-Acetyl-3Mercaptopropanoyl-CoA as a Function of Different Preincuba
tion Conditions

% of
Control

Preincubation
Components

Initiation
Components

TPP, CoASH, pyruvate

NAD+

Initial V elocity
(jumol/mir i/m g protein)
Inhibited
Control
2 .7 ± 0.3
0.2 ± 0.1

TPP, CoASH

NAD+, pyruvate

5.1 ± 0 .4

0.5 ± 0 .1

9.4

TPP, pyruvate, NAD+

CoASH

2.5 ± 0.4

1.3 ± 0 .0

51.2

TPP, CoASH, NAD+

pyruvate

3.3 ± 0.3

1.8 ± 0.6

53.7

TPP

N AD+, pyruvate, CoASH

3.3 ± 0.2

0 .6 ± 0.1

16.8

TPP, pyruvate

N AD+, CoASH

3.7 ± 0.3

1.2 ± 0.5

33.3

TPP, N A D +

pyruvate, CoASH

4 .7 ± 0.8

2.8 ± 0 .7

58.8

CoASH, pyruvate

TPP, N A D +

5 .0 ± 0.6

0 .6 ± 0.1

12.7

8.2

The enzyme was preincubated for 3 min a t 30°C in the presence of KPi, MgCl2,
and various components of the assay mixture. The reaction w as initiated by
the addition of those assay components not present during the preincubation.
The S-acetyl-3-mercaptopropanoyl-CoA, w hen included in the preincubation
m ixture, w as at a concentration of 67.5 /uM. O ther details of the experiment
can be found under "Experimental Procedures".
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Table 19. Inhibition of Pyruvate Dehydrogenase - Lipoate Acetyltransferase
The enzyme was preincubated for 3 min at room temperature in the presence of
TRIS-HC1, MgCL, TPP, and CoASH. Either pyruvate, lipoamide or neither
were included in The preincubation mixture. The reaction was initiated by the
addition of either pyruvate, lipoamide or both as indicated. Acetyl-CoA pro
duced was measured via the citrate synthase reaction. Other experimental
details can be found under "Experimental Procedures".
I = S-Acetyl-3-Mercaptopropanoyl-CoA (67.5 fiM)

Preincubation
Conditions
lipoamide
lipoamide, I
pyruvate
pyruvate, I
I

Initiating
Component
pyruvate
pyruvate
lipoamide
lipoamide
pyruvate, lipoamide
pyruvate, lipoamide

Specific Activity
(Amol/min/mg)
1.2 ± 0 .2
0.8 ± 0.2
1.1 ± 0 .2
0.4 ±0.1
1.0 ± 0.2
0.7 ± 0.2

Relative Activity
(%)
100
72
100
39
100
68

-8 4 -

Table 20. Inhibition o f D ihydrolipoyl Dehydrogenase
The enzyme protein was preincubated for 3 minutes at 30°C in the presence of
KP. and one substrate. The reaction was initiated by the addition of the
second substrate. A3 . q was measured spectrophotometrically. Other experi
mental details can be found under "Experimental Procedures".

I = S-Acetyl-3-Mercaptopropanoyl-CoA (67.5 /kM)
Dihydrolipoamide + NAD+

..^ Lipoamide + NADH + H+

Preincubation
Conditions

Initiating
Component

Dihydrolipoamide
Dihydrolipoamide, I
NAD+
NAD+. I
Lipoamide
Lipoamide, I
NADH
NADH. I

NAD+
NAD+
Dihydrolipoamide
Dihvdrolipoam ide
NADH
NADH
Lipoamide
Lipoamide

Specific Activity
(yumol/min/mg)
6.8
3.3
5.6
4.9
5.7
5.4
5.8
3.1

± 1.1
± 0 .8
±0.1
± 0.3
± 0.8
± 1.3
± 0 .2
± 0 .2

Relative
Activity
100
47.0
100
88.1
100
94.4
100
53.0

± 5.3
± 6.0
± 18.3
± 3.8
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Table 21. Inhibition of [ l- 14C]-Acetyl Group Incorporation into the Pyru
vate Dehydrogenase Complex
Experiment I

Inhibitor Concentration
( mM)
0

Acetyl Bound/PDH Complex
mol/mol
50.7

Acetyl Bound
% of Control
100

47.8

31.0

61.1

980.7

4.3

8.5

Experiment II

Inhibitor Concentration
UM)
0

Acetyl Bound/PDH Complex
mol/mol
34.5

Acetyl Bound
% of Control
100

47.8

21.9

63.6

119.6

17.8

51.7

239.2

7.1

20.7

478.4

1.5

5.2

Experiment I utilized porcine pyruvate dehydrogenase complex. Experiment II
utilized the bovine enzyme. The enzyme (0.2-0.22 mg protein) was preincu
bated at room temperature for 3 min. The preincubation mixture contained
KPi, MgCl., TPP, NADH, and ± S-acetyl-3-mercaptopropanoyl-CoA (the inhi
bitor). Tne reaction was initiated with [l- C]-acetyl-CoA. Other details of
the experiment are described in "Experimental Procedures".
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Table 22. Inhibition of Palm itoylcartine- and Pyruvate-Supported
Respiration by 3-Mercaptopropanoic Acid and S-Acetyl-3Mercaptopropanoic Acid
The mitochondria were preincubated 1 min in the presence of malate at which
time the inhibitor (~ 800 /xM) was added. ADP was added to the chamber 3
min after malate. The substrate was added to the chamber 4 min after malate.
Values are means ± S. E. The values are based on at least two assays for each
preparation of mitochondria. Figures in parentheses indicate the number of
mitochondrial preparations studied. All preparations of mitochondria had
RCR values larger than 4, using palmitoylcamitine as substrate. Other details
of the experiment are described under "Experimental Procedures".

Rat Liver Mitochondria
Palmitoylcarnitine-Supported Respiration
Respiration Rate
Inhibitor
(% of Control)
40 ±11(4)
3-mercaptopropanoic acid
32 ± 14(2)
S-acetyl-3-mercaptopropanoic acid
Pyruvate-Supported Respiration
Respiration Rate
Inhibitor
(% of Control)
57 ± 8(4)
3-mercaptopropanoic acid
56 ±20(2)
S-acetyl-3-mercaptopropanoic acid
Rat Heart Mitochondria
Palmitoylcarnitine-Supported Respiration
Respiration Rate
Inhibitor
(% of Control)
17 ± 15(3)
3-mercaptopropanoic acid
27
(1)
S-acetyl-3-mercaptopropanoic acid
Pyruvate-Supported Respiration
Respiration Rate
Inhibitor
(% of Control)
104 ± 0(2)
3-mercaptopropanoic acid
S-acetyl-3-mercaptopropanoic acid
99
(1)
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Table 23. Inhibition of Pyruvate-Supported Respiration in Rat Heart
Mitochondria by 3-Mercaptopropanoic Acid in the Presence of
Acetoacetate
The mitochondria were preincubated with primer. 3-Mercaptopropanoic acid
(final concentration was 840.7 /zM) was added to the chamber 30 sec after the
addition of primer. Acetoacetate was added to the chamber 1 min after the
addition of primer. Substrate was added to the chamber 4.5 min after the
addition of primer. Values are means ± S. E. The values are based on at least
two assays for each preparation of mitochondria. Figures in parentheses indi
cate the number of mitochondrial preparations studied. All preparations of
mitochondria had RCR values larger than 4, using palmitoylcarnitine as sub
strate. Other details of the experiment are described under "Experimental Pro
cedures" .
Conditions
Primer

Other
Additions

Substrate

Rate o f Respiration
(natom O /m in /m g)
Control
Inhibited

malate

p alm itoyl
carnitine

105.6 ± 10.7(2)

malate

pyruvate

2 74.2

a-K G a
a-K G

acetoacetate

a-K G

acetoacetate

a-K G

a a-K G = a-ketoglutarate

(1 )

7.4 ± 3 .2 (2 )

2 0 2 .3

(1 )

% of
Control

6.6

81.8

67 .4 ± 0 .0 (2 )

6 7 .4 ± 0 .0 ( 1 )

100.0

80 .9 ± 0 .0(2)

103.4 ± 0 .0 ( 2 )

127.8

pyruvate

2 38.2 ±

0 .0 (2 )

105.6 ± 3 .2 ( 2 )

4 4.3

pyruvate

2 0 9 .0 ±

3.2(2)

9 6.7 ± 3 .2 (1 )

4 6.2
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Figure 1. Schematic Representation of Fatty Acid Activation and Tran
sport Across the Mitochondrial Membranes
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Figure 2. P a th w a y o f L in o leic Acid D egradation

A, pathway proposed by Stoffel and Caesar85. B, modified pathway supported
by findings published by Kunau and Dommes , as well as Cuebas and
Schulz . Reactions catalyzed by: (1) acyl-CoA dehydrogenase; (2) enoyl-CoA
hydratase; (3) L-3-hydroxyacyl-CoA dehydrogenase; (4) 3-ketoacyl-CoA
thiolase; (5) 3-hydroxyacyl-CoA epimerase; (6) cis-A-trans-A -enoyl-CoA
isomerase; (7) 2,4-dienoyl-CoA reductase.
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Figure 3. Mitochondrial Metabolism of 3-Mercaptopropanoic Acid
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Specific Activity (nmol/min/mg protein)

Figure 4. Effect of Palm itoylcaraitine on A ctivity of Palmitoyl-CoA Syn
thetase in Rat Heart Mitochondria
The figure was generated from the experimental data in Table 2.
The curve is a theoretical curve based on linear regression analysis.
Other details of the experiment can be found under "Experimental
Procedures".
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Figure 5. Concentration Dependence of Inhibition by Malonyl-CoA and
Succinyl-CoA o f Carnitine Palm itoyltransferase A
CPT A activity was assayed by the radiochemical method. The
filled circles indicate malonyl-CoA. The opened circles indicate
succinyl-CoA. The figure was generated from the data in Table 8.
Other details of the experiment can be found under "Experimental
Procedures".
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Figure 6. Inhibition o f Pyruvate Dehydrogenase Complex by 3Mercaptopropanoyl-CoA and S-Acetyl-3-MercaptopropanoylCoA
A, As a Function of Concentration
B, As a Function of Time
A, The enzyme was preincubated for 3 minat 30°Cin the presence
of KPf, MgCl2, TPP, CoASH, pyruvate, and the inhibitor. The reac
tion was initiated with NAD+.
B, The enzyme was preincubated for 3 min at 30°C in the presence of
KPf, MgCL, TPP, CoASH, and pyruvate. The inhibitor was added
to provide Tor preincubation for the lengths of time indicated.
The solid line indicates S-acetyl-3-mercaptopropanoyl-CoA. The
dashed line indicates 3-mercaptopropanoyl-CoA.
Each value
represents the mean of a minimum of three assays. The curves are
theoretical curves generated by linear regresion analysis.
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Figure 7. Inhibition
of
Pyruvate
Dehydrogenase
by
3Mercaptopropanoy 1-CoA as a Function of Different Preincuba
tion Conditions
The enzyme was preincubated for 3 min at 30°C in the presence of
KPi, MgCl2, and various components of the assay mixture. The
reaction was initiated by the addition of those assay components not
present during the preincubation. The dashed line indicates the
presence of 30.5 fiM 3-mercaptopropanoyl-CoA in the preincubation
mixture.
Symbol

o
X
o
A

Preincubation
Components
TPP, CoASH, Pyruvate
TPP, NADH
/ TPP, NAD+, CoASH
L t p p , NAD+
TPP, Pyruvate
C TPP, CoASH
TPP, Pyruvate, NAD+
TPP
v. CoASH, Pyruvate

Initiating
Components
NAD+
CoASH, Pyruvate, NAD+
Pyruvate
CoASH .Pyruvate
NAD+, CoASH
NAD+, Pyruvate
CoASH
NAD+, Pyruvate, CoASH
TPP, NAD+
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Figure 7.
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Figure 8. Inhibition o f Pyruvate Dehydrogenase by S-Acetyl-3Mercaptoprqpanoyl-CoA as a Function of Different Preincuba
tion Conditions
The enzyme w as preincubated fo r 3 min at 30°C in th e presence of
KPi, MgCl2, and various components of th e assay m ixture. The
reaction w as initiated by th e addition of those assay components not
present during the preincubation. The dashed line indicates the
presence of 67.5 fxM S-acetyl-3-m ercaptopropanoyl-CoA in the
preincubation m ixture.
mbol
•
o

□
X

A

Preincubation
Components
TPP, CoASH. Pyruvate
TPP, NADH
TPP, CoASH
TPP, NAD+
(T PP, Pyruvate, NAD+
) TPP, CoASH, NAD+
i ( TPP
I TPP, pyruvate
LCoASH, Pyruvate

Initiation
Components
NAD+
CoASH, Pyruvate, NAD+
Pyruvate, NAD+
Pyruvate, CoASH
CoASH
Pyruvate
NAD+, Pyruvate, CoASH
NAD+, CoASH
TPP, NAD+

-9 7 -

Figure 8.
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Figure 9. S chem atic R ep rese n tatio n o f th e P y ru v a te D ehydrogenase Com
plex
E l = Pyruvate Dehydrogenase
E2 = Lipoate Acetyl Transferase
E3 = D ihydrolipoyl Dehydrogenase
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